Single-Cell Multi-Omics Analysis Reveals Tumor Microenvironment Remodeling, Genetic Instability, and Pathway Dysregulation in Primary Breast Cancer
This single-cell RNA sequencing report details profound biological shifts distinguishing normal breast tissue from primary tumors. UMAP visualizations show clear segregation of normal and malignant cell populations, with tumor epithelial cells exhibiting prevalent aneuploidy and widespread genomic instability. The tumor microenvironment undergoes extensive remodeling, marked by significant alterations in cell type proportions, enhanced cell-cell interactions, and global pathway dysregulation in tumor epithelial cells, cancer-associated fibroblasts, and tumor-associated macrophages. These findings collectively highlight the complex cellular and molecular landscape driving breast cancer progression.
Contents
- Dataset overview
- UMAP Visualization of Single-Cell Transcriptomic Data Colored by Key Metadata
- Major Cell Type Score and Ploidy Visualization on UMAP
- Celltype_subset Marker Expression Analysis
- Copy Number Variation Analysis in Breast Cancer Tumor and Unassigned Cells Grouped by Sample
- CNV-based UMAP Visualization of Cell Type, Ploidy, Condition, and Sample
- Minor Cell Type Population Analysis in Breast Tissue
- Immune Lymphoid Cell Subset Composition in Normal and Primary Breast Tumor Tissues
- Primary Breast Tumor Condition Shows Altered T Cell Subset Proportions
- Macrophage Cell Population Validation Across Samples
- Ploidy Analysis of Epithelial and Unassigned Cells in Breast Tissue
- 유방암 미세환경 내 세포-세포 상호작용 패턴 분석
- Primary Breast Tumor Cell-Cell Interaction Analysis
- Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Related Genes in Breast Tissue
- Condition-Specific Cell-Cell Interaction Patterns in Breast Tissue
- Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer
- Macrophage Condition-Specific Surfaceome Markers in Breast Tissue
- Fibroblast Condition-Specific Surfaceome Markers in Breast Tissue
- Cell-Type-Specific Surfaceome Marker Discovery in Breast Tissue
- Differential Expression of Cell Cycle-Related Genes in Breast Cancer Epithelial Cells: YWHAZ Upregulation
- Epithelial Cell Gene Ontology (GSA) Analysis: Condition and Ploidy-Specific Pathway Enrichment in Breast Tissue
- Gene Set Enrichment Analysis Reveals Widespread Pathway Dysregulation in Breast Cancer Microenvironment
- Discussion
- Query List
0. Dataset overview
Dataset Summary
- This dataset contains single-cell RNA-seq data from human Breast tissue.
- It comprises 88707 cells and 25535 genes.
- Key observational columns include sample, condition (primary_tumor, normal), cell type annotations (celltype_major, celltype_minor, celltype_subset), and ploidy_dec (Aneuploid, Diploid).
- The tumor origin cell type is Epithelial cell.
- Reference condition for differential analyses is 'normal'.
- Precomputed results stored include Cell-cell interaction (CCI), Differential Gene Expression (DEG), Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO/GSA) results, CNV estimates, and ploidy inference labels.
- Specific cell types available for DEG, GSEA, and GSA/GO analyses are: Endothelial cell, Epithelial cell, Fibroblast, ILC, Macrophage, Smooth muscle cell.
1. UMAP Visualization of Single-Cell Transcriptomic Data Colored by Key Metadata
[Analysis Visualization Results]...
Analysis Overview
This analysis presents UMAP (Uniform Manifold Approximation and Projection) plots generated from single-cell RNA-seq data, providing a two-dimensional visualization of cellular relationships based on gene expression profiles. The UMAPs are colored by various metadata features, including condition (normal vs. primary_tumor), sample (individual patient samples), celltype_major, celltype_minor, celltype_subset (different levels of cell type annotation), and ploidy_dec (ploidy inference: Aneuploid/Diploid). These visualizations are crucial for assessing the overall structure of the dataset, evaluating the quality of cell type annotations, checking for batch effects, and understanding the distribution of different biological states across the cell populations.
Visual Summary
Condition UMAP
The UMAP colored by condition shows a clear separation between cells originating from normal tissue and primary_tumor tissue. While there are distinct clusters largely dominated by one condition, some regions exhibit a mixture of both normal and tumor cells, particularly in areas likely representing immune or stromal infiltrates within the tumor microenvironment. The bulk of the primary_tumor cells form several large, distinct clusters.
Sample UMAP
The sample UMAP reveals that cells from different patient samples are generally well-mixed within their respective cell type clusters. This indicates successful integration of data from multiple samples, suggesting that batch effects due to individual patient variability or experimental processing are largely mitigated, allowing for robust comparisons across samples.
Celltype_major, Celltype_minor, and Celltype_subset UMAPs
These three UMAPs progressively display more granular cell type annotations:
- Celltype_major: Major cell types such as Epithelial cell, Stromal cell, T cell, Myeloid cell, and Endothelial cell form well-separated clusters, indicating distinct gene expression profiles that define these broad cell lineages. unassigned cells are minimal.
- Celltype_minor: This level further refines major types into more specific populations like Fibroblast, Macrophage, T cell CD4+, T cell CD8+, ILC, etc. These populations also form largely coherent and distinct clusters, suggesting good resolution of these finer cell types.
- Celltype_subset: This represents the highest resolution of cell type annotation, showing subtypes like Luminal epithelial cell, Macrophage (M1), Macrophage (M2B), T cell (Treg), Endothelial tip cell, etc. The clusters generally remain well-defined, albeit with some areas of overlap, which is expected as subtypes often represent continuous states or closely related populations. The presence of unassigned cells is also minimal at this level.
Ploidy_dec UMAP
The ploidy_dec UMAP shows Aneuploid cells predominantly localized within specific clusters, which largely overlap with the primary_tumor condition in the 'condition' UMAP and specifically with the Epithelial cell populations in the cell type UMAPs. Diploid cells are widespread across most clusters, particularly those associated with normal tissue and non-malignant cell types (e.g., stromal, immune, endothelial cells) within both normal and tumor contexts. A small number of Unclear ploidy cells are also present, mostly intermingled with diploid cells.
Biological Interpretation
The UMAP visualizations provide strong evidence for distinct cellular landscapes in normal breast tissue versus primary breast tumors. The clear separation of primary_tumor cells from normal cells on the condition UMAP highlights the profound transcriptomic changes associated with cancer development. The tumor microenvironment is complex, and the observed mixing of normal and primary_tumor cells in certain regions likely represents the presence of infiltrating immune cells, stromal cells, and endothelial cells that are part of the tumor-associated stroma, even if originating from normal tissue.
The robust clustering of cells by celltype_major, celltype_minor, and celltype_subset confirms the quality of the cell type annotations and the effectiveness of the dimensionality reduction method in capturing biological distinctions. The low number of unassigned cells across all annotation levels suggests comprehensive cell type identification within the dataset. The specific cell types identified, such as Luminal epithelial cell (a common subtype in breast cancer), various Macrophage polarizations (M1, M2A, M2B, M2C, M2D known for their roles in tumor immunity), and diverse T cell subsets (e.g., Treg, Cytotoxic, Th17), indicate the richness of the dataset for studying tumor immunology and stromal interactions.
A key finding from the ploidy_dec UMAP is the strong association of Aneuploid cells with the primary_tumor condition and, more specifically, with the Epithelial cell clusters. Given that Epithelial cell is designated as the tumor origin cell type in this breast tissue dataset, this observation is highly consistent with the known genomic instability and aneuploidy characteristic of epithelial-derived solid tumors like breast cancer. Aneuploidy, or the presence of an abnormal number of chromosomes, is a hallmark of cancer and contributes to tumor heterogeneity and progression PubMed search: aneuploidy cancer hallmarks. The detection of aneuploidy predominantly within the epithelial compartment reinforces these cells as the malignant population. The widespread presence of Diploid cells in other clusters further confirms the health and non-malignant nature of stromal, immune, and endothelial populations, which typically maintain a diploid state.
Annotation Notes
The consistency of clustering patterns across different annotation levels (major, minor, subset) and the clear biological distinctions observed (e.g., condition-specific cell populations, aneuploidy in epithelial tumor cells) suggest high-quality cell type annotation and data processing. The UMAPs effectively illustrate the cellular heterogeneity within the breast tissue samples and provide a reliable foundation for subsequent downstream analyses, such as differential gene expression or cell-cell interaction studies, within well-defined cell populations. The successful integration of samples indicates that comparisons across individuals can be made with confidence.
2. Major Cell Type Score and Ploidy Visualization on UMAP
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes single-cell RNA-seq data on a UMAP embedding, displaying major cell type scores, inferred ploidy status, and the assigned major cell type annotations. The goal is to understand the spatial distribution of different cell types and their ploidy state within the dataset, particularly in the context of breast tissue with primary tumor and normal conditions.
Visual Summary
The UMAP plots reveal several distinct clusters representing various cell populations.
Cell Type Score Distribution:
- T cell (HiCAT_major_score: T cell): High T cell scores are concentrated in a distinct cluster on the left side of the UMAP, indicating a clear separation of this immune cell population.
- B cell (HiCAT_major_score: B cell): B cell scores are highest in a small, distinct cluster within the broader immune compartment, slightly separate from the main T cell cluster.
- Myeloid cell (HiCAT_major_score: Myeloid cell): Myeloid cells show high scores in a cluster located towards the top-left of the UMAP, suggesting another distinct immune cell group.
- Mast cell (HiCAT_major_score: Mast cell): Mast cells form a smaller, more localized cluster with high scores, largely overlapping with some myeloid cell areas.
- Endothelial cell (HiCAT_major_score: Endothelial cell): Endothelial cells exhibit high scores primarily in a cluster towards the upper-middle region of the UMAP.
- Stromal cell (HiCAT_major_score: Stromal cell): Stromal cells show high scores in a large, somewhat diffuse cluster on the bottom-left and extending towards the center of the UMAP, suggesting heterogeneity within this population.
- Epithelial cell (HiCAT_major_score: Epithelial cell): Epithelial cells exhibit very high scores in a prominent cluster located on the bottom-right and central-right part of the UMAP.
- Ploidy Status (ploidy_dec): The ploidy_dec plot shows a clear segregation of cells based on their ploidy.
- Aneuploid cells (dark red): These cells are predominantly found within the large cluster on the bottom-right and central-right of the UMAP.
- Diploid cells (pale yellow): Diploid cells constitute the majority of the remaining clusters across the UMAP, including the immune and stromal populations.
- Unclear cells (dark blue): A small proportion of cells are labeled as 'Unclear' in their ploidy status and are scattered.
- Major Cell Type Annotation (celltype_major): The celltype_major plot directly displays the assigned cell identities using distinct colors.
- Epithelial cells (Epi, orange/red): These cells largely correspond to the aneuploid region observed in the ploidy_dec plot and the high-scoring epithelial cluster.
- Stromal cells (light green): These cells occupy the bottom-left and central regions, aligning with the high stromal cell scores and diploid status.
- Immune cells (T cell, Myeloid cell, Endothelial cell, B cell, Mast cell - various colors): These populations form distinct clusters on the left and upper parts of the UMAP, consistent with their respective score distributions and generally diploid.
- Unassigned cells (dark blue): A small population of unassigned cells is present, mainly scattered or forming small, less distinct clusters.
Biological Interpretation
The visualizations provide strong evidence for the distinct cellular composition of the breast tissue samples.
- Robust Cell Type Identification: The major cell type scores align very well with the assigned celltype_major annotations. For example, the regions with high "HiCAT_major_score: T cell" precisely match the T cell cluster in the celltype_major plot, and similarly for Epithelial, Stromal, Myeloid, and Endothelial cells. This consistency suggests that the cell type annotations are robust and well-supported by the underlying gene expression profiles.
- Identification of Tumor Cells: A critical observation is the strong correlation between Epithelial cell annotations and Aneuploid status. Given that "Tumor origin celltype: Epithelial cell" and the tissue is Breast (often implying breast carcinoma), the large Aneuploid cluster, predominantly composed of Epithelial cells, is highly indicative of the malignant tumor cell population. Aneuploidy is a hallmark of cancer, and its enrichment within the epithelial compartment strongly supports its identification as the tumor cells [1]. The normal epithelial cells, likely present in the normal samples, would be expected to be diploid and might cluster separately or as a minor diploid component within the epithelial population.
- Immune and Stromal Compartments: The UMAP clearly delineates distinct clusters for various immune cell types (T cells, Myeloid cells, B cells, Mast cells) and stromal cells (Fibroblasts, Smooth muscle cells, Endothelial cells, etc., derived from celltype_minor context). These non-malignant cells are predominantly Diploid, as expected for healthy host cells. Their spatial separation from the aneuploid epithelial tumor cells highlights the complex cellular ecosystem of the tumor microenvironment and surrounding normal tissue.
Annotation Notes
The consistency between the calculated major cell type scores and the assigned celltype_major labels is excellent, reinforcing the quality and accuracy of the cell type annotations in this dataset. The distinct clustering of different cell types and the clear segregation of aneuploid vs. diploid populations further validate the biological integrity of the data representation. The small number of "unassigned" cells or "unclear" ploidy cells do not significantly detract from the overall clarity of the major populations.
---
References:
- Aneuploidy as a hallmark of cancer:
PubMed search: "aneuploidy cancer hallmark"
3. Celltype_subset Marker Expression Analysis
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a dot plot illustrating the expression patterns of identified marker genes across various celltype_subset populations derived from single-cell RNA-seq data of human breast tissue. The purpose is to visually confirm the distinct molecular identities of these cell subsets based on their unique marker gene expression profiles. The markers were selected to include surfaceome-only genes, which is beneficial for potential downstream experimental validation methods like flow cytometry.
Visual Summary
The dot plot displays celltype_subset populations on the y-axis and marker genes on the x-axis. Each dot represents the expression of a specific gene in a given cell subset. The size of the dot correlates with the fraction of cells within that group expressing the gene (non-zero expression), while the color intensity indicates the mean expression level of the gene in that group. On the right side, a bar chart shows the total number of cells for each celltype_subset.
The plot reveals a clear, diagonal-like pattern of highly expressed and specific marker genes for most annotated celltype_subset populations. This pattern, emphasized by the red boxes, indicates strong specificity for the selected markers and good separation between cell types. The majority of celltype_subset groups show distinct clusters of genes with high expression (large, dark red dots) largely restricted to their assigned cell type, with minimal off-target expression in other groups.
Biological Interpretation
The marker gene expression patterns strongly support the assigned biological identities of the various celltype_subset populations in the human breast tissue dataset:
Endothelial Cell Lineage
- Endothelial cell and Endothelial tip cell populations show enrichment for genes like ACKR1 (DARC), ANGPT2, and ESM1. ACKR1 is a known atypical chemokine receptor expressed on endothelial cells [GeneCards: ACKR1]. ANGPT2 and ESM1 are associated with angiogenesis and endothelial function [GeneCards: ANGPT2], [GeneCards: ESM1].
- Lymphatic Endothelial cell specifically expresses PDPN (podoplanin) and PROX1, which are canonical markers for lymphatic endothelial cells and crucial for lymphatic vessel development [GeneCards: PDPN], [GeneCards: PROX1].
Fibroblasts
Fibroblasts exhibit a robust and specific signature defined by numerous extracellular matrix (ECM) components and related genes, including DCN (decorin), LUM (lumican), multiple COL genes (COL1A1, COL1A2, COL3A1, COL5A1, COL6A2), FAP (Fibroblast Activation Protein), FBLN1, FBLN2, PDGFRA, and LOXL1. FAP is particularly notable as a marker for activated fibroblasts, including cancer-associated fibroblasts (CAFs), which play critical roles in tumor microenvironment remodeling [PubMed Search: "FAP cancer-associated fibroblasts"].
Innate Lymphoid Cells (ILCs)
The different ILC subsets show distinct but related expression profiles:
- ILC1 expresses GZMK and CD7, consistent with cytotoxic effector functions.
- ILC2 is characterized by GATA3 and RORA, key transcription factors for ILC2 development and function, involved in type 2 immune responses [GeneCards: GATA3], [GeneCards: RORA].
- ILCreg (regulatory ILCs) show expression of regulatory markers such as FOXP3, CTLA4, and TNFRSF18 (GITR), indicating an immunosuppressive role [GeneCards: FOXP3], [GeneCards: CTLA4].
- LTI (Lymphoid Tissue inducer) cells express RORC and NOTCH3, consistent with their role in lymphoid organogenesis and maintenance [GeneCards: RORC].
Epithelial Cells
- Luminal epithelial cell is identified by luminal-specific keratins like KRT8, KRT18, and KRT19, along with MUC1 and CLDN4 [GeneCards: KRT8].
- Mammary epithelial cell shows expression of KRT5, KRT7, KRT14, and KRT17, which can be associated with basal or myoepithelial components and general mammary epithelial identity [GeneCards: KRT5]. This distinction between luminal and basal/general mammary epithelial markers is consistent with breast tissue biology.
Macrophages
Macrophage subsets display varying expression of general and specific markers:
- General macrophage markers like CD74 and MSR1 are broadly present. CD74 acts as an invariant chain for MHC class II molecules [GeneCards: CD74].
- Macrophage (M1) shows some specific markers related to inflammatory responses, such as IRF5 [GeneCards: IRF5].
- Macrophage (M2A) and (M2C) both express MSR1, often associated with anti-inflammatory or wound-healing functions [GeneCards: MSR1]. M2C also shows PPARG and SOCS3, reflecting distinct regulatory roles [GeneCards: PPARG].
- Macrophage (M2B) expresses IL1R2, while Macrophage (M2D) shows AQP3 and LTF. These suggest further functional specialization within the M2 spectrum.
Mast Cells
Mast cells are clearly identified by canonical markers KIT (CD117), a receptor tyrosine kinase essential for mast cell development and survival, and tryptases TPSAB1 and TPSB2, which are specific mast cell proteases [GeneCards: KIT], [GeneCards: TPSAB1]. SRGN (serglycin) is also expressed, involved in granule storage [GeneCards: SRGN].
Smooth Muscle Cells
Smooth muscle cells are well-defined by key contractile proteins and associated genes, including ACTA2 (alpha-smooth muscle actin), CALD1 (caldesmon 1), TPM2 (tropomyosin 2), TAGLN (transgelin), MYL9 (myosin light chain 9), and MYH11 (myosin heavy chain 11) [GeneCards: ACTA2].
T Cell Lineage
The T cell subsets exhibit highly specific marker expression consistent with their functional roles:
- T cell (Cytotoxic) expresses CD8A, GZMB (granzyme B), and GZMK, indicative of CD8+ T cell-mediated cytotoxicity [GeneCards: CD8A], [GeneCards: GZMB].
- T cell (Naive) is identified by SELL (CD62L), a cell adhesion molecule involved in lymphocyte homing to lymph nodes [GeneCards: SELL].
- T cell (Tfh) (Follicular helper T cell) expresses PDCD1 (PD-1), a key immune checkpoint marker, and CD84, important for germinal center interactions [GeneCards: PDCD1].
- T cell (Th1) (Type 1 helper T cell) shows STAT1 and IFNGR1, reflecting its role in interferon-gamma mediated immunity [GeneCards: STAT1].
- T cell (Th17) and T cell (Th22) both express RORC, the master transcription factor for Th17 development, which also plays a role in Th22 differentiation [GeneCards: RORC].
- T cell (Th2) (Type 2 helper T cell) is marked by GATA3 and STAT6, crucial for allergic and anti-parasitic immune responses [GeneCards: GATA3], [GeneCards: STAT6].
- T cell (Treg) (Regulatory T cell) is robustly characterized by the master regulatory transcription factor FOXP3, along with CTLA4 and TNFRSF18, confirming their immunosuppressive identity [GeneCards: FOXP3], [GeneCards: CTLA4].
Annotation Notes
The comprehensive marker gene expression patterns observed in the dot plot provide strong evidence supporting the quality and accuracy of the celltype_subset annotations within this AnnData object. The clear, non-overlapping expression of specific markers for the vast majority of cell types indicates that these subsets are transcriptionally distinct and well-resolved. The inclusion of surfaceome-only markers further strengthens the utility of these annotations for downstream applications requiring cell isolation or targeted imaging. This level of granularity and distinct marker expression suggests a reliable foundation for further biological investigations into the roles of these specific cell subsets in breast tissue, across different conditions (primary_tumor vs. normal), or in response to various perturbations.
4. Copy Number Variation Analysis in Breast Cancer Tumor and Unassigned Cells Grouped by Sample
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates copy number variations (CNVs) in single-cell RNA-seq data focusing on 'Epithelial cell' (the defined tumor origin cell type) and 'unassigned' cells from breast tissue samples. Cells were grouped by sample, and CNVs were estimated and visualized using a heatmap of log2(CNR) (Copy Number Ratio). A summary heatmap and bar chart of significantly amplified cytogenetic bands across these samples were also generated to highlight recurrent amplifications. The primary goal is to identify common chromosomal alterations in tumor-associated cells and distinguish them from samples identified as diploid.
Visual Summary
CNV Heatmap (log2(CNR))
The first heatmap visualizes log2(CNR) values across genomic spots for individual samples.
- Distinct Patterns by Ploidy: Samples explicitly labeled as "Diploid Patient" (e.g., Diploid Patient_5, Diploid Patient_6) generally show minimal copy number alterations, appearing largely blue (slight deletion) or light red (slight amplification) but without prominent, widespread changes. This pattern is consistent with their diploid classification, validating the ploidy_dec annotation.
- Widespread Alterations in Tumor Samples: In contrast, samples labeled simply "Patient" (e.g., Patient_1, Patient_2) exhibit extensive and often distinct patterns of copy number alterations. These samples display clear regions of strong amplification (dark red) and deletion (dark blue) across multiple chromosomes, indicating widespread aneuploidy. This finding is characteristic of tumor cells and aligns with the expectation that 'Epithelial cell' from primary tumors would harbor significant genomic instability.
- Recurrent Alterations: Several regions show recurrent amplifications or deletions across multiple "Patient" samples. For instance, amplifications are frequently observed on chromosomes 8, 11, 17, and 20, while deletions are also visible in other regions. These recurrent changes may represent driver events in breast cancer progression.
Summary of Significantly Amplified Regions
The second figure provides a detailed summary of significant amplifications by cytogenetic band.
- Frequency of Amplifications: The bar chart on the right indicates the frequency with which each cytogenetic band is significantly amplified across the analyzed samples. The most frequently amplified regions include:
1p34.3:1p34.2 (Frequency ~0.67)
1q21.1:1q23.2 (Frequency ~0.50)
1q32.1:1q32.1 (NFASC) (Frequency ~0.83)
1q41:1q42 (Frequency ~0.42)
7p22.2:7p21.1 (Frequency ~0.70)
7p11.2:7q21.1 (Frequency ~0.50)
7q21.3:7q22.1 (Frequency ~0.42)
8p11.21:8q12.1 (Frequency ~0.33)
8q22.1:8q23.1 (EIF3E) (Frequency ~0.42)
8q23.2:8q24.13 (Frequency ~0.50)
8q24.3:9p24.2 (Frequency ~0.70)
10q26.3:11p15.5 (Frequency ~0.50)
11q13.4:11q21 (Frequency ~0.50)
15q26.3:16p13.3 (Frequency ~0.50)
16p13.3:16p13.3 (Frequency ~0.50)
17q25.3:18p11.31 (Frequency ~0.33)
- Patient-Specific Amplification Scores: The summary heatmap shows the specific amplification score (likely average log2(CNR) or a derived metric) for each cytogenetic band in each patient. Darker blue squares indicate higher amplification scores. For instance, Patient_7 shows strong amplifications in 1q32.1 (NFASC) and 8q23.2:8q24.13. Patient_9 exhibits high amplification in 8p11.21:8q12.1, 8q22.1:8q23.1 (EIF3E), and 8q23.2:8q24.13.
Biological Interpretation
The analysis of CNVs in 'Epithelial cell' and 'unassigned' populations provides critical insights into the genomic landscape of breast cancer.
- Tumor-specific Aneuploidy: The clear distinction between 'Diploid Patient' samples and 'Patient' samples in the main heatmap strongly indicates that the latter group likely represents tumor samples exhibiting significant aneuploidy, a hallmark of cancer. The cells from the 'Diploid Patient' group, despite being derived from patients, show genomic stability consistent with a normal or benign state, or potentially a distinct tumor subtype that retains diploidy. This observation aligns with the ploidy_dec annotation.
- Recurrent CNVs in Breast Cancer: The identified recurrent amplifications in regions such as 1q, 7p/q, and 8q are frequently reported in various cancers, including breast cancer. For example:
- 1q amplifications: Common in breast cancer and often associated with aggressive tumor phenotypes. PubMed: 1q breast cancer
- 8q amplifications: A well-known region for oncogene amplification (e.g., MYC, not explicitly called here but often co-amplified). The observed amplification in 8q22.1:8q23.1 and 8q23.2:8q24.13 regions is noteworthy.
- Candidate Oncogenes: The mention of specific genes within amplified regions, such as NFASC (Neurofascin) in 1q32.1 and EIF3E (Eukaryotic Translation Initiation Factor 3 Subunit E) in 8q22.1, provides specific targets for further investigation.
- NFASC encodes a cell adhesion molecule and has been implicated in cell migration, invasion, and metastasis in some cancers, including breast cancer, where its dysregulation can impact tumor progression. GeneCards: NFASC
- EIF3E is part of the eukaryotic translation initiation factor 3 complex, which plays a crucial role in protein synthesis. Dysregulation of translation initiation factors is frequently observed in cancer and can contribute to increased proliferation, survival, and drug resistance of cancer cells. Its amplification suggests a potential role in driving protein synthesis and cell growth in these tumors. GeneCards: EIF3E
- 'Unassigned' Cell Population: The inclusion of 'unassigned' cells in this analysis is crucial. Given the prevalence of aneuploidy in tumor samples, it is plausible that a significant fraction of these 'unassigned' cells might indeed be tumor cells that were difficult to classify based on transcriptomic profiles alone, but whose genomic instability strongly points to a malignant origin. This suggests that CNV analysis can aid in identifying tumor cells that might otherwise be overlooked by standard cell typing methods.
Clinical or Translational Implications
- Biomarker Identification: The identified recurrent CNVs and specific gene amplifications (e.g., NFASC, EIF3E) could serve as potential diagnostic or prognostic biomarkers for breast cancer, aiding in patient stratification.
- Patient Stratification: The clear distinction between diploid and aneuploid patterns could be used to classify patients, potentially identifying those with more aggressive tumor biology requiring tailored therapeutic approaches.
- Annotation Validation: The CNV analysis supports and potentially refines cell type annotations, particularly by distinguishing genuinely diploid cells from those exhibiting tumor-associated aneuploidy, which might be critical for accurately interpreting downstream functional analyses.
5. CNV-based UMAP Visualization of Cell Type, Ploidy, Condition, and Sample
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes single-cell RNA-sequencing data on a Uniform Manifold Approximation and Projection (UMAP) embedding, specifically constructed using Copy Number Variation (CNV) estimates. The UMAP plots are colored by various metadata features: major cell type, minor cell type, ploidy status (ploidy_dec), condition (primary_tumor vs normal), and individual sample. This allows for an assessment of how these biological and technical factors contribute to the CNV landscape and cell population structure within the dataset.
Visual Summary
celltype_major and celltype_minor plots:
- Epithelial cells (Epi, orange/red tones) predominantly occupy a distinct cluster (or clusters) in the upper and some lower-left regions of the UMAP. This region largely overlaps with cells identified as aneuploid and originating from primary tumors.
- Stromal cells (light green), T cells (teal), Endothelial cells (dark red), and Myeloid cells (yellow) tend to cluster separately, primarily in the central and lower-right regions, which correspond to diploid cell populations.
- The distribution of minor cell types provides a more granular view, further confirming the distinct clustering of Epithelial cells from other stromal and immune cell populations.
ploidy_dec plot:
- There is a clear and robust separation between "Aneuploid" (dark red) and "Diploid" (yellow) cells on the CNV UMAP.
- Aneuploid cells form several prominent clusters, indicating substantial structural genomic alterations in these cell populations.
- Diploid cells form a large, contiguous cluster, suggesting a more homogenous genomic state for these cells.
- The "Unclear" category for ploidy is minimal, indicating high confidence in the ploidy classifications.
condition plot:
- Cells from the "primary_tumor" condition (purple) largely overlap with the regions identified as "Aneuploid" in the ploidy_dec plot. This strong correspondence highlights the characteristic genomic instability of tumor cells.
- Cells from the "normal" condition (dark red) primarily reside in the regions identified as "Diploid," as expected for non-malignant tissues.
- This strong separation by condition on the CNV-based UMAP confirms that the embedding effectively captures tumor-specific genomic alterations.
sample plot:
- While distinct clusters related to ploidy and condition are evident, individual samples contribute to both aneuploid and diploid populations, reflecting the cellular heterogeneity within each sample.
- Some samples appear to contribute more heavily to specific regions, which could indicate inter-sample variability in CNV patterns or differences in the cellular composition of the sampled tissue. However, there is no strong evidence of batch effects completely separating samples within the expected aneuploid/diploid regions.
Biological Interpretation
The UMAP embedding, specifically configured to emphasize CNV patterns, provides critical insights into the genomic landscape of the analyzed breast tissue samples.
- Tumor-specific Aneuploidy: The most striking observation is the clear segregation of cells based on their ploidy status, with "Aneuploid" cells forming distinct clusters that are almost exclusively derived from the "primary_tumor" condition. This aligns perfectly with the understanding that cancer cells, particularly epithelial cells (the designated Tumor origin celltype), often exhibit widespread chromosomal instability and aneuploidy as a hallmark of malignancy.
- Cell Type-Specific Genomic States: Epithelial cells, identified as the tumor origin cell type, predominantly co-localize with the aneuploid clusters and the primary tumor condition. In contrast, stromal cells, T cells, endothelial cells, and myeloid cells mainly occupy the diploid regions, consistent with their role as components of the tumor microenvironment or normal tissue, where they typically maintain a diploid genomic state.
- Data Quality and Annotation Validation: The robust separation of aneuploid/diploid cells and primary tumor/normal conditions on the CNV-based UMAP strongly validates the quality of the CNV estimates and the accuracy of the ploidy_dec and condition annotations. It also reinforces the biological relevance of the cell type assignments, especially distinguishing malignant epithelial cells from non-malignant cells.
Annotation Notes
The UMAP projections effectively capture significant biological variance related to copy number variations. The distinct clustering of cells based on ploidy, condition, and expected cell types (e.g., epithelial cells with aneuploidy in tumors) provides strong evidence for the quality of the CNV estimation and the biological integrity of the dataset. The minimal presence of "unassigned" cells and "unclear" ploidy status further supports the robustness of the current annotations.
6. Minor Cell Type Population Analysis in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a stacked bar plot showing the proportional distribution of minor cell types across individual samples for both normal breast tissue and primary breast tumors. The visualization allows for a direct comparison of cellular composition shifts associated with tumor development.
Visual Summary
The plot displays the relative proportions of 13 minor cell types (Dendritic cell, Endothelial cell, Epithelial cell, Fibroblast, ILC, Macrophage, Mast cell, NK cell, Smooth muscle cell, T cell CD4+, T cell CD8+, unassigned) for 4 normal samples and 10 primary tumor samples.
Key Observations:
- Normal Tissue Composition: Normal breast tissue samples are predominantly composed of Epithelial cells (dark orange), which consistently represent a very high proportion (often >70-80%) across all normal samples. Endothelial cells (red) and Fibroblasts (light orange) are also present in notable, but smaller, proportions. Other immune cell types are largely sparse or absent.
- Primary Tumor Tissue Composition: In contrast, primary tumor samples exhibit a more diverse and heterogeneous cellular landscape.
- The proportion of Epithelial cells is generally reduced and highly variable across tumor samples, ranging significantly (e.g., from <20% to ~70%).
- Fibroblasts (light orange) show a marked increase in relative abundance in many tumor samples compared to normal tissue, often becoming a major component of the tumor microenvironment.
- Immune cell infiltration is evident, with Macrophages (yellow), T cell CD4+ (light green), and T cell CD8+ (teal) populations appearing in varying, but generally higher, proportions in tumor samples. Dendritic cells, Mast cells, and NK cells are also more frequently observed, albeit still in lower overall percentages.
- The "unassigned" cell population (dark blue) is notably elevated in some primary tumor samples, suggesting either technical challenges in annotation within complex tumor environments or the presence of distinct, uncharacterized cell states.
- Inter-sample Heterogeneity: Primary tumor samples display considerably more heterogeneity in their cellular composition compared to the relatively uniform normal samples, reflecting the diverse nature of individual tumors.
Biological Interpretation
The observed shifts in minor cell type populations between normal breast tissue and primary tumors provide critical insights into the remodeling of the tumor microenvironment (TME) during breast cancer progression.
- Epithelial Cell Dominance in Normal Tissue: The high proportion of epithelial cells in normal breast tissue is expected, given that the mammary gland is an epithelial organ and epithelial cells are the tumor-originating cell type.
- Stromal Cell Remodeling (Fibroblasts, Endothelial Cells): The significant increase in Fibroblasts within the primary tumor microenvironment points to the activation of cancer-associated fibroblasts (CAFs). CAFs are known to play crucial roles in promoting tumor growth, invasion, metastasis, and therapeutic resistance by secreting growth factors, cytokines, and extracellular matrix components PubMed Search: Cancer-associated fibroblasts breast cancer. Endothelial cells, while present in both conditions, are essential for tumor angiogenesis, supporting tumor growth through neo-vascularization.
- Immune Cell Infiltration: The increased presence of diverse immune cell types, particularly Macrophages and T cells (CD4+ and CD8+), in the primary tumor samples is indicative of an active immune response within the TME.
- Macrophages (often tumor-associated macrophages or TAMs) can be highly plastic, adopting pro- or anti-tumor functions (M1 vs. M2 polarization) depending on the microenvironmental cues GeneCards: CD68. Their increased presence often correlates with poor prognosis in breast cancer.
- T cells (CD4+ and CD8+) represent the adaptive immune response. While cytotoxic CD8+ T cells are crucial for anti-tumor immunity, their function can be suppressed within the TME. CD4+ T cells include helper T cells and regulatory T cells (Tregs), which can either promote or inhibit anti-tumor responses.
- Tumor Heterogeneity: The substantial inter-sample variability among primary tumors underscores the inherent biological complexity and unique microenvironmental composition of individual breast cancers, which can influence tumor behavior and treatment response.
- "Unassigned" Cells: The higher proportion of "unassigned" cells in some tumor samples could suggest either the presence of highly plastic, dedifferentiated, or stress-induced cell states that are difficult to categorize with current markers, or potential limitations in the initial cell type annotation for these complex samples. Further investigation might be warranted to characterize these populations.
Clinical or Translational Implications
- Biomarker Discovery and Prognosis: The altered proportions of specific stromal and immune cell types, such as Fibroblasts and Macrophages, could serve as prognostic biomarkers for breast cancer patients. For example, a high infiltration of certain CAF subtypes or M2-like macrophages is often associated with more aggressive disease.
- Therapeutic Targeting: Understanding the cellular composition of the TME can inform therapeutic strategies. Targeting CAFs or specific immune cell populations (e.g., macrophage polarization, T cell checkpoints) are active areas of research for improving breast cancer outcomes. For instance, therapies aimed at depleting CAFs or modulating macrophage function are being explored to disrupt the pro-tumorigenic niche PubMed Search: Tumor microenvironment targeted therapy breast cancer.
- Patient Stratification: The observed heterogeneity among primary tumors suggests that a one-size-fits-all approach to breast cancer therapy may be suboptimal. Stratifying patients based on their TME cellular composition could enable more personalized and effective treatment regimens.
7. Immune Lymphoid Cell Subset Composition in Normal and Primary Breast Tumor Tissues
[Analysis Visualization Results]...
Analysis Overview
This analysis presents a stacked bar plot visualizing the relative proportions of different lymphoid cell subsets, including T cells, Innate Lymphoid Cells (ILCs), and Natural Killer (NK) cells, across individual samples from normal breast tissue and primary breast tumors. The celltype_major category "T cell" was initially targeted, but the resulting celltype_subset breakdown broadly encompasses various lymphoid populations, reflecting a comprehensive view of the immune lymphoid compartment. Each bar represents 100% of the lymphoid cells identified within a given sample, allowing for a direct comparison of the internal composition of these immune cells between the two conditions.
Visual Summary
The visualization clearly separates samples into two conditions: 'normal' (4 samples) and 'primary_tumor' (10 samples).
- Normal Tissue Composition: In normal breast tissue, the lymphoid compartment appears to be largely dominated by LTI (Lymphoid Tissue Inducer) cells and NK cells, which together form a substantial portion (often >60-70%) of the cells within this major category across most normal samples. ILCs, specifically ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), and ILCreg, are also consistently present, contributing smaller but notable proportions. Various T cell subsets, such as T cell (Cytotoxic), T cell (Naive), and T cell (Th1), are observed but generally constitute a smaller fraction compared to LTI and NK cells in this specific lymphoid cell group.
- Primary Tumor Tissue Composition: In primary tumor samples, while LTI and NK cells still represent a significant component, there appear to be subtle but consistent shifts in the relative proportions of T cell subsets compared to normal tissue.
- T cell (Cytotoxic) and T cell (Naive) populations are consistently present in tumor samples, and in some tumor samples, their combined proportions visually appear slightly elevated relative to the baseline proportions seen in normal tissue.
- T cell (Treg) cells (dark teal) are detectable across several primary tumor samples, suggesting their presence within the tumor microenvironment.
- T cell (Th1) cells (light green-yellow) are also observed in tumor samples.
- The overall composition across tumor samples shows more variability than in normal samples, with different patients exhibiting slightly different immune lymphoid profiles. The "unassigned" population (dark blue) remains a relatively minor component in both conditions.
Biological Interpretation
The observed shifts in lymphoid cell populations between normal breast tissue and primary tumors provide insights into the immune response dynamics within the tumor microenvironment (TME).
- Dynamic Lymphoid Compartment: The inclusion of ILCs and NK cells alongside T cells under the broader "T cell major" category highlights the complex interplay of innate and adaptive lymphoid immunity in the breast. ILCs and NK cells are critical for early immune surveillance and can shape subsequent adaptive T cell responses PMID: 31036814.
- TME Remodeling: The presence and potential relative enrichment of adaptive T cell subsets, particularly Cytotoxic T cells and Regulatory T cells (Tregs), in primary tumors compared to normal tissue, are characteristic features of the TME.
- Cytotoxic T cells are central effectors in anti-tumor immunity, directly killing cancer cells. Their presence suggests an ongoing, albeit potentially suppressed, anti-tumor immune response GeneCards: CD8A.
- Tregs are known to suppress anti-tumor immunity, fostering an immunosuppressive TME that can facilitate tumor growth and evasion of immune attack GeneCards: FOXP3. Their consistent detection in tumor samples is a common finding in various cancers.
- Th1 cells are typically associated with pro-inflammatory, anti-tumor responses through the production of cytokines like IFN-gamma.
- Innate Lymphoid Cells (ILCs) and NK cells: While dominant in normal tissue, their relative proportions might shift in the TME. NK cells play a crucial role in innate anti-tumor immunity by recognizing and killing stressed or transformed cells without prior sensitization. ILCs are diverse and contribute to tissue homeostasis, inflammation, and anti-tumor responses depending on their subset (e.g., ILC1 often pro-inflammatory/anti-tumor, ILC2/3 context-dependent).
Clinical or Translational Implications
The compositional changes in the lymphoid compartment in primary breast cancer have significant clinical and translational implications:
- Prognostic Biomarkers: The balance between anti-tumor effector cells (like Cytotoxic T cells, Th1 cells, NK cells) and immune-suppressive cells (like Tregs) within the TME can be a critical determinant of patient prognosis. A higher cytotoxic T cell to Treg ratio, for example, is often associated with better clinical outcomes in various cancers.
- Immunotherapy Response: Understanding the specific T cell and ILC/NK cell profiles in individual tumors can inform patient stratification for immunotherapeutic interventions. Tumors with a higher infiltration of activated cytotoxic T cells might be more responsive to immune checkpoint blockade, while those dominated by Tregs might require strategies to deplete or reprogram these suppressive cells PubMed search: breast cancer immunotherapy immune microenvironment.
- Target Identification: The specific subset composition can highlight potential therapeutic targets. For instance, modulating the activity of particular ILC subsets or enhancing NK cell function could represent novel approaches to bolster anti-tumor immunity.
- Personalized Medicine: The observed inter-patient heterogeneity in tumor immune composition underscores the need for personalized approaches in breast cancer management, where immune profiling of individual tumors could guide tailored treatment strategies. Further investigation into the functional states of these cells (e.g., exhaustion markers, cytokine production) would provide a deeper understanding beyond just population counts.
8. Primary Breast Tumor Condition Shows Altered T Cell Subset Proportions
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates statistically significant differences in the proportions of T cell subsets between primary breast tumor tissue and normal breast tissue samples. The plot_box_for_celltype_population_with_signif_difference tool was used to compare cell type proportions (specifically at the 'subset' taxonomic level within the 'T cell' major population) between the 'primary_tumor' and 'normal' conditions, identifying subsets with a p-value less than 0.1 and a log2 fold change greater than 0.1.
Visual Summary
The boxplots illustrate the proportions of three T cell subsets that showed statistically significant differences between conditions:
- Th2 (T helper 2) cells: The proportion of Th2 cells appears higher in primary tumor samples compared to normal samples (median primary_tumor ≈ 2.5%, median normal ≈ 1.25%). This difference is borderline statistically significant (p = 0.08).
- LTI (Lymphoid Tissue inducer) cells: The proportion of LTI cells is significantly lower in primary tumor samples compared to normal samples (median primary_tumor ≈ 42%, median normal ≈ 54%). This difference is highly statistically significant (p ≤ 0.01). Note: While typically classified as innate lymphoid cells (ILCs), LTI cells are presented here as a relevant subset identified in the context of this T cell-focused analysis, likely reflecting the dataset's specific cell type annotation hierarchy.
- Tfh (T follicular helper) cells: The proportion of Tfh cells is notably higher in primary tumor samples compared to normal samples (median primary_tumor ≈ 4.5%, median normal ≈ 2.5%). This difference is statistically significant (p ≤ 0.05).
Biological Interpretation
The observed shifts in T cell subset populations in the primary breast tumor microenvironment suggest a complex interplay of immune responses:
- Increased Th2 cells in tumors: Th2 cells are primarily associated with humoral immunity and can promote an immunosuppressive environment in cancer through the secretion of cytokines like IL-4, IL-5, and IL-13. An elevated Th2 proportion in primary breast tumors could indicate a shift towards a tumor-promoting immune response, potentially dampening anti-tumor Th1-mediated immunity and contributing to immune evasion PubMed search: Th2 cells cancer immunosuppression.
- Decreased LTI cells in tumors: Lymphoid tissue inducer (LTI) cells, a subset of Innate Lymphoid Cells (ILCs), are crucial for the development and maintenance of lymphoid structures. Their significant reduction in primary tumors might reflect a disruption in the local lymphoid architecture or an impaired ability to mount effective adaptive immune responses, as organized lymphoid structures are often important for proper immune cell activation and tumor clearance PubMed search: ILC3 cancer immunology. Given their high absolute proportions in normal tissue compared to other T cell subsets, their decrease in tumor suggests a substantial change in the overall immune landscape.
- Increased Tfh cells in tumors: T follicular helper (Tfh) cells are critical for providing help to B cells, supporting germinal center formation and antibody production. An increased proportion of Tfh cells in primary breast tumors could indicate an active B cell response within the tumor microenvironment. While B cells and Tfh cells can contribute to anti-tumor immunity by generating anti-tumor antibodies, they can also promote tumor growth or chronic inflammation in some contexts, depending on the specificity and quality of the B cell response GeneCards: T follicular helper cells.
Collectively, these findings suggest that the breast tumor microenvironment is characterized by alterations in specific T cell and innate lymphoid populations, favoring an immune landscape that may suppress effective anti-tumor immunity (e.g., higher Th2) and potentially impair immune organization (e.g., lower LTI), while also showing an active but potentially complex B cell-supporting response (e.g., higher Tfh).
Clinical or Translational Implications
These differential proportions of T cell subsets between normal and primary tumor breast tissue have several potential clinical and translational implications:
- Prognostic Biomarkers: The proportions of Th2, LTI, and Tfh cells, particularly their ratios or absolute counts, could serve as prognostic biomarkers for disease progression or recurrence in breast cancer patients.
- Therapeutic Targets: Understanding these shifts provides potential avenues for immunotherapy. Strategies aimed at reducing Th2 cell activity, restoring LTI cell populations, or modulating the functional output of Tfh cells could be explored to enhance anti-tumor immunity in breast cancer PubMed search: Immunotherapy breast cancer T cells.
- Patient Stratification: These immune profiles might help stratify patients who would benefit most from specific immunotherapeutic approaches. For instance, patients with high Th2 or low LTI might benefit from therapies designed to counteract immunosuppression or restore lymphoid function.
9. Macrophage Cell Population Validation Across Samples
[Analysis Visualization Results]...
Analysis Overview
This analysis visualizes the distribution of cells identified as 'Macrophage' (based on the celltype_minor annotation) across individual samples, separated by 'normal' and 'primary_tumor' conditions. The plot_celltype_population tool was used with a targets parameter specifically set to 'Macrophage', indicating a focus on this particular cell type.
Visual Summary
The bar plots display the selected 'Macrophage' population for each sample. Under the 'normal' condition, four samples are shown, and under the 'primary_tumor' condition, ten samples are displayed. In both conditions, for every single sample, the bar representing 'Macrophage' reaches 100% on the y-axis. This indicates that all cells considered for this specific visualization in each sample are annotated as 'Macrophage'.
Biological Interpretation
This visualization primarily serves as a confirmation of the presence and accurate selection of 'Macrophage' cells within the dataset. For each sample included in these plots, 100% of the cells being displayed are indeed identified as 'Macrophage' according to the celltype_minor annotation.
It is crucial to understand that this plot does not represent the overall proportion of macrophages relative to all other cell types within each tissue sample. Instead, it confirms that when the dataset is filtered or focused specifically on 'Macrophage' cells, those selected cells are consistently identified as such across all analyzed samples and conditions.
Biologically, the presence of macrophages in both normal breast tissue and primary tumor samples is highly expected. Macrophages are integral components of the immune system and play diverse roles in tissue homeostasis, inflammation, and disease, including cancer. In the context of breast cancer, tumor-associated macrophages (TAMs) are well-known to infiltrate the tumor microenvironment and can significantly influence tumor progression, metastasis, and response to therapy PubMed search: tumor associated macrophages breast cancer.
Annotation Notes / Limitations
While this plot validates the successful identification and selection of the 'Macrophage' population, it does not provide insights into key biological questions such as:
- Relative Abundance: It does not show how the proportion of macrophages compares to other cell types (e.g., epithelial cells, fibroblasts) within each sample or between normal and tumor conditions.
- Cell State Shifts/Heterogeneity: It does not resolve the known heterogeneity within the macrophage population, such as distinct polarization states (e.g., M1-like vs. M2-like macrophages), which are crucial for understanding their functional roles in cancer. These subtypes are present in the celltype_subset column (e.g., Macrophage (M1), Macrophage (M2A)) and would require further analysis to explore. To analyze such heterogeneity or condition-associated changes in macrophage abundance, subsequent analyses focusing on relative proportions or subtype distribution would be necessary.
10. Ploidy Analysis of Epithelial and Unassigned Cells in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates the ploidy status (Aneuploid, Diploid, or Unclear) of epithelial and unassigned cells across various normal and primary breast tumor samples. Ploidy, the number of complete sets of chromosomes in a cell, is a critical feature often altered in cancer, with aneuploidy (abnormal chromosome number) being a hallmark of many solid tumors, including breast cancer. Given that epithelial cells are identified as the tumor origin cell type, examining their ploidy provides insight into genomic instability associated with tumorigenesis.
Visual Summary
The bar plots display the proportion of aneuploid, diploid, and unclear cells for epithelial and unassigned cell populations within each sample, segregated by 'normal' and 'primary_tumor' conditions.
- Normal Condition: In the normal samples, the vast majority of cells are diploid (light orange bars dominating). Only one normal sample (Patient_3_4AF75L_RNA) shows a minor proportion (~20%) of aneuploid cells (dark red bar), while the other three normal samples are almost exclusively diploid. This indicates a largely stable genome in normal breast tissue.
- Primary Tumor Condition: In stark contrast, primary tumor samples exhibit a significant and highly variable presence of aneuploid cells.
- Several tumor samples (e.g., Patient_11_3FCDEL_RNA, Patient_5_35A4AL_RNA, Patient_6_4C2E5L_RNA, Patient_12_44F0AL_RNA) show a very high proportion of aneuploid cells, exceeding 90% in some cases. This suggests pervasive genomic instability within these tumors.
- Other tumor samples display a more mixed ploidy profile, with varying proportions of aneuploid and diploid cells. For instance, Patient_13_3D385L_RNA has roughly 65% aneuploid cells, while Patient_9_3B3E9L_RNA and Patient_14_43E7BL_RNA show approximately 45% and 30% aneuploid cells, respectively.
- Some tumor samples (e.g., Patient_7_35EE8L_RNA, Patient_15_45CB0L_RNA, Patient_14_43E7CL_RNA, Patient_10_3C7D1L_RNA) present lower but still notable levels of aneuploidy, ranging from about 10% to 25%.
- A small 'Unclear' population (light green) is observed in a few primary tumor samples, though it constitutes a very minor fraction of the total cell population.
Biological Interpretation
The observed shift from predominantly diploid cells in normal tissue to a high and variable prevalence of aneuploid cells in primary tumors is a strong indicator of neoplastic transformation and genomic instability, a hallmark of cancer progression.
- Aneuploidy as a Hallmark of Cancer: The dramatically increased aneuploidy in epithelial and unassigned cells from primary tumors compared to normal tissue is consistent with aneuploidy being a critical driver and consequence of tumorigenesis in breast cancer [1]. Aneuploidy often arises from errors in chromosome segregation during cell division, leading to an imbalance in gene dosage that can promote cell proliferation, survival, and drug resistance.
- Tumor Heterogeneity: The variability in aneuploidy levels among different primary tumor samples highlights the significant inter-patient heterogeneity characteristic of breast cancer. Some tumors are highly aneuploid, suggesting extensive genomic chaos, while others retain a more diploid-like state, potentially indicating different evolutionary paths, stages, or molecular subtypes of cancer [2]. This heterogeneity can influence tumor behavior, metastatic potential, and response to therapy.
- Implications for 'Unassigned' Cells: The ploidy patterns observed in 'unassigned' cells, which are grouped with epithelial cells for this analysis, likely reflect either misclassified epithelial tumor cells or other cell types within the tumor microenvironment that have acquired aneuploidy, possibly due to genomic instability induced by the tumor. However, given the 'Tumor origin celltype: Epithelial cell' context, it is more plausible that these 'unassigned' cells largely represent epithelial cells whose precise subtype could not be resolved, and thus contribute to the overall tumor ploidy landscape.
Clinical or Translational Implications
The detection of aneuploidy in tumor-origin epithelial cells has several clinical implications:
- Diagnostic and Prognostic Biomarker: Aneuploidy, particularly the degree of chromosomal instability (CIN) that leads to aneuploidy, is a well-established prognostic factor in various cancers, including breast cancer. High levels of aneuploidy can correlate with aggressive tumor behavior, higher recurrence rates, and poorer patient outcomes [3, 4].
- Therapeutic Targeting: Understanding the ploidy status and underlying mechanisms of genomic instability could inform therapeutic strategies. Tumors with high aneuploidy might be more sensitive to specific therapies that target cell cycle checkpoints or induce mitotic catastrophe. Conversely, they might also be prone to developing resistance due to their high genomic plasticity.
- Monitoring Disease Progression: Monitoring changes in aneuploidy could potentially serve as a biomarker for disease progression or treatment response.
---
References:
- Aneuploidy as a hallmark of cancer:
PubMed Search: Aneuploidy cancer hallmark
- Tumor Heterogeneity:
PubMed Search: Breast cancer tumor heterogeneity aneuploidy
- Prognostic value of aneuploidy:
PubMed Search: Aneuploidy breast cancer prognosis
- Chromosomal Instability in Cancer:
PubMed Search: Chromosomal instability cancer prognosis
11. 유방암 미세환경 내 세포-세포 상호작용 패턴 분석
[Analysis Visualization Results]...
Analysis Overview
본 분석은 단일 세포 RNA 시퀀싱 데이터를 기반으로 AnnData 객체에서 추출된 세포-세포 상호작용(Cell-Cell Interaction, CCI) 패턴을 normal 및 primary_tumor 조건별로 시각화한 결과입니다. 특히, Epithelial cell, Fibroblast, Macrophage, T cell CD4+, T cell CD8+ 등 주요 세포 유형 간의 리간드-수용체 상호작용에 초점을 맞추었습니다. CellPhoneDB를 사용하여 계산된 상호작용 중 각 조건에서 최대 80개의 유의미한 상호작용이 점도표(dot plot) 형태로 제시되었으며, 점의 크기는 상호작용의 통계적 유의성(-log10(p-value))을, 색상은 상호작용 리간드 및 수용체의 평균 발현 강도(log2(mean))를 나타냅니다. 특히 primary_tumor 조건에서는 종양 세포의 특성을 반영하는 이수성(Aneuploid) 상피세포(Epi)가 포함되어 분석되었습니다.
Visual Summary
Normal 조건에서의 세포-세포 상호작용:
- normal 조직에서는 주로 Fibroblast (Fib)와 이배체 상피세포(Diploid Epi) 간, 그리고 각 세포 유형 내(Fib|Fib, Diploid Epi|Diploid Epi) 상호작용이 두드러집니다.
- 세포외 기질(ECM) 관련 상호작용: COL11A1, COL14A1, COL1A1, COL3A1, COL4A1, COL6A2, COL6A3, COL8A1 등 다양한 콜라겐(Collagen)과 인테그린(integrin_a1b1_complex, integrin_a2b1_complex) 복합체 간의 상호작용이 매우 활발하게 관찰됩니다. 이는 정상 조직의 구조 유지와 세포 접착에 중요한 역할을 합니다.
- 성장 인자 신호: IGF1-integrin_a6b1_complex, PDGFA-PDGFRA, PDGFB-PDGFRB, TGFB2-TGFbeta_receptor_1, TGFB3-TGFbeta_receptor_1 등 성장 인자 관련 상호작용도 확인됩니다.
Primary Tumor 조건에서의 세포-세포 상호작용:
- primary_tumor 조직에서는 normal 조건보다 훨씬 다양하고 복잡한 상호작용 패턴이 나타납니다.
- 세포 유형 다양성 증가: Macrophage (Mac)와 T cell (T CD4+, T CD8+) 등 면역세포 간, 그리고 이수성 상피세포(Aneuploid Epi)와 섬유아세포(Fib), 대식세포(Mac) 간의 상호작용이 광범위하게 나타납니다. 특히 Aneuploid Epi가 다양한 상호작용에 적극적으로 참여하고 있음이 관찰됩니다.
ECM 리모델링 및 종양 관련 신호:
- normal 조건과 유사하게 콜라겐-인테그린 상호작용이 여전히 중요하지만, 이제 Aneuploid Epi가 이러한 상호작용에 적극적으로 관여하여 종양 미세환경의 ECM 리모델링을 시사합니다.
- SPP1-integrin_avb1_complex: 이 상호작용은 primary_tumor에서 Fib|Mac, Aneuploid Epi|Aneuploid Epi, Mac|T CD4+ 등 여러 세포 쌍에서 두드러지게 활성화되어 있으며, 강도(log2(mean))도 높은 경향을 보입니다.
- CXCL12-CXCR4: Fib|Mac, Fib|Aneuploid Epi, Mac|T CD4+ 등에서 나타나며, 종양 성장 및 전이에 중요한 역할을 합니다.
- VEGF 신호: VEGFA-FLT1, VEGFA-KDR, VEGFA-NRP1, VEGFA-NRP2 등 혈관신생(angiogenesis)과 관련된 VEGF 패밀리 상호작용이 primary_tumor에서 활발합니다.
- WNT 신호: WNT2-FZD4, WNT7A-FZD4, WNT5A-FZD4, WNT2B-FZD4, WNT5A-ROR2, WNT7B-FZD4 등 다양한 WNT 경로 상호작용이 Aneuploid Epi와 Fib를 포함한 여러 세포 쌍에서 관찰됩니다.
- HGF-MET, IL6-IL6R: 이들도 primary_tumor에서 나타나는 중요한 상호작용으로, 종양 성장, 침윤 및 면역 조절과 관련이 있습니다.
Biological Interpretation
이러한 세포-세포 상호작용의 변화는 유방암 미세환경의 재구성을 명확히 보여줍니다.
- ECM 리모델링 및 기질 활성화: normal 조직에서는 콜라겐-인테그린 상호작용이 조직 항상성 유지에 기여하지만, primary_tumor에서는 암세포(Aneuploid Epi)가 섬유아세포와 함께 ECM 리모델링에 적극적으로 참여하여 종양 세포의 침윤 및 전이를 촉진하는 환경을 조성합니다. 이는 암 관련 섬유아세포(CAFs)의 활성화와 관련이 깊습니다.
- 면역 미세환경의 변화: primary_tumor에서 대식세포와 T 세포 간의 상호작용이 증가하고, CXCL12-CXCR4 축과 같은 면역 조절 관련 상호작용이 나타나는 것은 종양 면역 환경이 활성화되거나 면역 억제적 방향으로 재편되고 있음을 시사합니다. 특히 Mac|T CD4+와 같은 상호작용은 종양 관련 대식세포(TAMs)가 T 세포 반응을 조절하는 메커니즘을 반영할 수 있습니다.
- 종양 성장 및 진행 촉진 신호: primary_tumor에서 SPP1-integrin, CXCL12-CXCR4, VEGF-VEGFR, HGF-MET, IL6-IL6R, WNT 등 다양한 성장 인자 및 신호 전달 경로가 활발하게 나타나는 것은 종양 세포의 증식, 생존, 혈관신생 및 전이를 직접적으로 지원하는 핵심적인 메커니즘을 나타냅니다. 예를 들어, SPP1 (Osteopontin)은 종양 진행, 면역 억제 및 항암 치료 저항성에 중요한 역할을 하는 것으로 알려져 있습니다 PubMed search: SPP1 cancer therapy. CXCL12-CXCR4 축은 암세포의 이동과 전이, 그리고 면역 세포 유입에 관여합니다 GeneCards: CXCR4. VEGF는 혈관신생의 주요 조절인자입니다 PubMed search: VEGF angiogenesis cancer.
- 이수성 상피세포의 역할: Aneuploid Epi는 유방암의 주요 종양 세포 집단으로, 이들이 섬유아세포, 대식세포 및 다른 이수성 상피세포와 광범위하게 상호작용하는 것은 종양 세포 자체가 미세환경 조성 및 종양 진행의 주도적인 역할을 수행함을 보여줍니다.
Clinical or Translational Implications
이러한 세포-세포 상호작용 패턴의 차이는 유방암의 진단 및 치료 전략 개발에 중요한 시사점을 제공합니다.
- 치료 표적 발굴:
- primary_tumor에서 특이적으로 증가하거나 강화된 SPP1-integrin, CXCL12-CXCR4, VEGF-VEGFR, HGF-MET, IL6-IL6R, WNT와 같은 리간드-수용체 축은 유방암 치료를 위한 잠재적인 치료 표적이 될 수 있습니다. 특히, 이미 임상적으로 검증되었거나 개발 중인 VEGF/VEGFR, HGF/MET, CXCR4 억제제들은 이러한 CCI 분석 결과를 통해 환자 선별 및 병용 요법 개발에 활용될 수 있습니다.
- 예를 들어, SPP1 또는 그 수용체 인테그린을 표적하는 것은 종양 세포의 증식과 전이를 억제하고 면역 억제 환경을 개선하는 데 유용할 수 있습니다.
- 특정 인테그린(integrin_avb1_complex, integrin_avb3_complex)이 다양한 종양 관련 상호작용에 관여하므로, 이들을 선택적으로 억제하여 종양 세포-ECM 및 종양 세포-기질 세포 간의 유착 및 신호 전달을 방해하는 전략도 고려해볼 수 있습니다 PubMed search: integrin therapy cancer.
- 바이오마커 개발:
- primary_tumor에서 특이적으로 발현이 증가하거나 활성화되는 특정 리간드/수용체 쌍은 유방암의 예후 예측, 치료 반응 모니터링 또는 조기 진단을 위한 바이오마커로 활용될 가능성이 있습니다.
- 병용 요법의 근거:
- 복잡하게 얽힌 CCI 네트워크는 단일 표적 치료의 한계를 시사하며, 여러 경로를 동시에 표적하는 병용 요법 개발의 필요성을 강조합니다. 예를 들어, 혈관신생 억제제(VEGF 타겟)와 면역 관문 억제제(immune checkpoint inhibitors) 또는 종양-기질 상호작용 억제제를 병용하는 전략을 탐색할 수 있습니다.
- 실험적 검증:
- 이러한 분석 결과는 환자 유래 오가노이드 모델(patient-derived organoids), 공동 배양 시스템(co-culture systems), 또는 생체 내 종양 모델(in vivo tumor models)을 활용한 추가적인 기능 연구를 위한 강력한 가설을 제공합니다. 특정 CCI를 저해하거나 강화했을 때 종양 세포의 행동 변화 및 미세환경 재구성에 미치는 영향을 평가하여 치료적 유효성을 검증할 수 있습니다.
12. Primary Breast Tumor Cell-Cell Interaction Analysis
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interaction (CCI) patterns in breast tissue under 'normal' and 'primary_tumor' conditions, utilizing single-cell RNA sequencing data. The plot_cci_dots tool was used to visualize the most significant and strong ligand-receptor interactions between different cell types for each condition. The dot size represents the negative log10 of the p-value (significance), and the color intensity indicates the mean expression level (strength) of the interaction, with warmer colors (yellow/green) signifying higher mean expression. We focused on the top 80 interactions by default. This comparison highlights how cell communication networks are altered in the tumor microenvironment (TME) compared to normal tissue, providing insights into potential mechanisms of tumor progression and identifying therapeutic targets.
Visual Summary
CCI for Normal Condition
- The 'normal' condition plot displays a relatively sparse network of cell-cell interactions.
- Interactions are primarily observed between Fibroblast and Endothelial cell pairs, Smooth muscle cell and Endothelial cell pairs, and Diploid Epithelial cell with stromal components like Fibroblast and Smooth muscle cell.
- Notable ligand-receptor pairs often involve integrins (e.g., COL1A1_integrin_a1b1_complex, COL3A1_integrin_a1b1_complex) which mediate cell-extracellular matrix (ECM) and cell-cell adhesion, reflecting the structural integrity of normal tissue.
- Chemokine signaling such as CXCL12-CXCR4 is present, suggesting basal immune surveillance or stromal communication.
- The mean expression levels for most interactions in normal tissue are generally lower (cooler colors like blue/purple) compared to those in the tumor condition, indicating less intense communication.
CCI for Primary Tumor Condition
- The 'primary_tumor' condition plot shows a markedly denser and more complex network of cell-cell interactions compared to the normal condition, with a greater number of highly active (brighter yellow/green dots) interactions.
- Crucially, Aneuploid Epithelial cell pairs (likely representing malignant tumor cells) demonstrate extensive interactions with various stromal cells, including Fibroblast, Endothelial cell, Macrophage, and Smooth muscle cell. This underscores the active role of malignant cells in remodeling their microenvironment.
- Interactions involving Fibroblast cells (potentially cancer-associated fibroblasts, CAFs) are particularly pronounced, with strong signals with Macrophage, Endothelial cell, and Aneuploid Epithelial cell pairs.
- Endothelial cell interactions are highly active, especially with Fibroblast and Aneuploid Epithelial cell, suggesting robust angiogenic processes within the tumor.
- Several ligand-receptor pairs show significantly increased mean expression (brighter colors) in the tumor. These include various integrin complexes (e.g., COL1A1_integrin_a1b1_complex, FN1_integrin_a5b1_complex, FBN1_integrin_a2b1_complex), chemokine axes (CXCL12-CXCR4, CCL2-CCR2), and growth factors (VEGFA_NRP1, PGF_FLT1_complex, ANGPT2-TEK).
- Immune-related interactions, such as those involving T cell CD4+ (e.g., with Fibroblast or Endothelial cell) and Macrophage, are more evident, indicating active immune modulation within the TME.
Biological Interpretation
The striking differences in CCI between normal and primary tumor breast tissue reflect profound changes in the cellular ecosystem during tumorigenesis and progression.
- Tumor-Stromal Remodeling: The extensive interactions of Aneuploid Epithelial cells with Fibroblasts, Endothelial cells, and Macrophages highlight the critical role of the tumor microenvironment (TME) in supporting tumor growth and invasion. Fibroblasts are likely reprogrammed into cancer-associated fibroblasts (CAFs), which are known to secrete ECM components and growth factors that promote tumor cell proliferation, survival, and metastasis [GeneCards: FAP].
- Increased ECM-mediated Interactions: The prominent and often upregulated integrin-mediated interactions (e.g., COL1A1, COL1A2, COL3A1, COL6A1, FN1, FBN1, LAMC1 integrin complexes) in the tumor condition signify extensive remodeling of the extracellular matrix. This ECM provides physical support, signaling cues, and scaffolds for cell migration and invasion, critical processes in cancer progression. Integrin signaling can also promote tumor cell survival and therapeutic resistance [PubMed: Integrin signaling cancer].
- Angiogenesis and Vascular Remodeling: The strong and numerous interactions involving Endothelial cells with Aneuploid Epithelial cells and Fibroblasts, particularly through growth factor pathways like VEGFA-NRP1, PGF-FLT1, and ANGPT2-TEK, indicate active angiogenesis. This process is essential for supplying nutrients and oxygen to the rapidly growing tumor, and for facilitating metastasis [PubMed: Angiogenesis cancer].
- Immune Cell Recruitment and Modulation: Enhanced chemokine signaling, specifically CXCL12-CXCR4 and CCL2-CCR2, suggests active recruitment of various immune cells, including T cells and macrophages, into the TME. While CXCL12-CXCR4 can attract both pro-tumorigenic cells (e.g., myeloid-derived suppressor cells, some regulatory T cells) and anti-tumorigenic cells, its overexpression is often associated with poor prognosis and metastasis in breast cancer [GeneCards: CXCL12]. Macrophages, particularly M2-like subsets observed in the TME, can switch their phenotype to become pro-tumorigenic, promoting angiogenesis, immune suppression, and metastasis [PubMed: Tumor associated macrophages].
- Ploidy-specific Interactions: The clear distinction between Diploid Epithelial cell and Aneuploid Epithelial cell interactions in the tumor plot underscores that the malignant, aneuploid cells are the primary drivers of these altered communication networks. This confirms the specific involvement of transformed cells in shaping the tumor microenvironment.
Clinical or Translational Implications
The identified differential cell-cell interactions offer compelling insights for therapeutic development and patient stratification in breast cancer:
- Targeting Integrin-mediated Adhesion: The upregulation of various integrin complexes in the tumor, particularly those involving Aneuploid Epithelial cells and Fibroblasts, suggests that targeting specific integrin receptors could disrupt tumor cell adhesion, migration, and invasion, potentially hindering metastasis. Small molecule inhibitors or antibodies against specific integrins (e.g., αvβ3, α5β1) are under investigation in cancer therapies [PubMed: Integrin inhibitors cancer].
- Anti-angiogenic Strategies: The strong activation of VEGFA-NRP1, PGF-FLT1, and ANGPT2-TEK pathways confirms the importance of angiogenesis in breast cancer. Existing anti-angiogenic drugs, such as bevacizumab (targeting VEGFA), could be further optimized or combined with other therapies, or novel agents targeting NRP1, FLT1, or TEK could be explored [PubMed: Anti-angiogenic therapy breast cancer].
- Modulating Chemokine Axes: The CXCL12-CXCR4 and CCL2-CCR2 axes are critical for immune cell trafficking and can promote an immunosuppressive TME. Disrupting these axes, for example, with CXCR4 antagonists or CCR2 inhibitors, could impede the recruitment of pro-tumorigenic immune cells (e.g., macrophages, Tregs) and enhance anti-tumor immune responses [PubMed: Chemokine receptor inhibitors cancer].
- Targeting CAF-mediated Interactions: The prominent role of Fibroblasts in tumor interactions suggests that therapies aimed at reprogramming CAFs or disrupting their communication with tumor cells could be beneficial. This might involve targeting specific CAF-secreted factors or receptors involved in their activation [PubMed: CAF targeted therapies].
- Biomarker Identification: Specific ligand-receptor pairs with high activity in the primary tumor, especially those involving Aneuploid Epithelial cells, could serve as diagnostic or prognostic biomarkers, or predictors of response to targeted therapies. Further validation studies are warranted to explore their clinical utility.
13. Cell-Cell Interaction Analysis of Immune Checkpoint and Cell Cycle Related Genes in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates cell-cell interactions (CCI) mediated by a curated set of genes relevant to immune checkpoint and cell cycle pathways. Using CellPhoneDB results derived from single-cell RNA-seq data of breast tissue, we compare interaction patterns between normal tissue and primary tumor conditions. The plot_cci_dots tool visualizes significant ligand-receptor pairs, their interaction strength (mean expression), and statistical significance (p-value) across various interacting cell types. This allows for a deeper understanding of altered cellular communication in the tumor microenvironment.
Visual Summary
The provided dot plots illustrate significant cell-cell interactions for selected ligand-receptor pairs in both "normal" and "primary_tumor" conditions.
- Axes: The X-axis represents specific ligand-receptor pairs (e.g., AREG-EGFR, TGFB1-TGFbeta_receptor1), which are a subset of the initially requested immune checkpoint and cell cycle-related genes that showed significant interactions. The Y-axis denotes interacting cell type pairs (e.g., "ILC|Fib" implies interaction between ILC and Fibroblast).
- Dot Size: The size of each dot is inversely proportional to the -log10(p-value), where larger dots indicate higher statistical significance (lower p-value) of the interaction.
- Dot Color: The color of each dot represents the log2(mean) expression level of the interacting ligand-receptor pair. Brighter colors (green-yellow) indicate higher mean expression, suggesting stronger potential interaction.
- Normal Condition: In normal breast tissue, prominent interactions are observed involving Diploid Epi (likely normal epithelial cells) with Fibroblast (Fib), Endothelial cell (Endo), and other Diploid Epi cells. TGF-beta signaling (e.g., TGFB1-TGFbeta_receptor1/2, TGFB2-TGFbeta_receptor1/2) and EGFR signaling (e.g., AREG-EGFR, HBEGF-EGFR, TGFA-EGFR) are evident. Interactions also involve ILC (Innate Lymphoid Cells) and Endo cells.
- Primary Tumor Condition: The primary tumor condition displays a more diverse and often more significant pattern of interactions, particularly involving Aneuploid Epi cells (likely tumor epithelial cells). Aneuploid Epi cells show strong interactions with Fibroblasts. Interactions are also seen among Fib, Endo, Mac (Macrophages), ILC, and T CD4+ cells. The color scale for mean expression is higher in the tumor (up to 3.0 log2(m)) compared to normal (up to 2.0 log2(m)), suggesting increased expression of some ligand-receptor pairs.
Biological Interpretation
The analysis highlights critical changes in cellular communication pathways involving growth factors and their receptors, which are instrumental in both cell cycle regulation and immune modulation, between normal breast tissue and primary tumors.
- Dominance of TGF-beta Signaling in Both Normal and Tumor Contexts, with Specific Tumor-Associated Alterations:
- Normal Tissue Homeostasis: In normal tissue, TGF-beta signaling (TGFB1-TGFbeta_receptor1/2, TGFB2-TGFbeta_receptor1/2, TGFB1-TGFBR3, TGFB2-TGFBR3) is crucial for maintaining tissue homeostasis, regulating cell proliferation, differentiation, and extracellular matrix deposition. We observe interactions primarily involving Diploid Epi, Fibroblast, Endothelial, and ILC cell types.
- Tumor Microenvironment Remodeling: In the primary tumor, TGF-beta interactions remain highly prominent and appear even more pervasive and potent (larger, brighter dots) across various cell types, especially those involving Aneuploid Epi and Fibroblasts. Notably, TGFB1-TGFbeta_receptor1 and TGFB1-TGFbeta_receptor2 show strong signals between Fibroblasts themselves, and between Fibroblasts and Aneuploid Epi cells. This indicates an activated and likely pro-tumorigenic role of TGF-beta in the tumor microenvironment (TME), contributing to tumor growth, immune evasion, and fibrosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900010/.
- Integrin-mediated TGF-beta Activation: The appearance of TGFB1_integrin_avB6_complex interactions, particularly involving Aneuploid Epi and Fibroblasts in the tumor, is highly significant. Integrin αvβ6 is a key activator of latent TGF-beta, especially in cancer and fibrotic diseases. Its presence indicates a mechanism for localized, robust activation of TGF-beta signaling that promotes tumor invasiveness and immunosuppression within the TME https://pubmed.ncbi.nlm.nih.gov/33139886/.
- Elevated EGFR Signaling in Tumor-Associated Stromal Cells:
- EGFR ligands (AREG, HBEGF, TGFA) interacting with EGFR are observed in both conditions. In the tumor, Endothelial cells show notable self-interactions (Endo|Endo) and interactions with Diploid Epi cells via EGFR ligands. This suggests altered growth factor signaling that could support angiogenesis and stromal cell proliferation within the tumor. While Aneuploid Epi to Fib interaction involving EGFR ligands is present, it's not as broadly dominant as TGF-beta signaling in this specific view.
- Specific Cell-type Interactions in the Tumor Microenvironment:
- The emergence of interactions involving Aneuploid Epi (tumor epithelial cells) with Fibroblasts (Aneuploid Epi|Fib) is a hallmark of tumor progression, highlighting critical cross-talk that drives cancer phenotypes.
- Immune cells like ILC and T CD4+ are observed engaging in interactions in the tumor context, such as ILC|Aneuploid Epi with TGFB1-TGFbeta_receptor1, suggesting direct communication between immune and tumor cells that can influence immune responses. Macrophages (Mac|Fib) also show prominent interactions, likely reflecting their role in shaping the TME.
- Implications for Immune Checkpoint and Cell Cycle Control:
- While classical immune checkpoint ligands (like PD-L1/CD274) were part of the initial gene list, the strongest signals in these plots are from growth factor pathways (EGFR, TGF-beta). However, these pathways are deeply interconnected with immune evasion and cell cycle dysregulation. For example, TGF-beta is a potent immunosuppressor that can inhibit anti-tumor immune responses, effectively acting as an "immune checkpoint" for lymphocyte function. EGFR signaling directly drives cell proliferation and can also influence the expression of immune modulatory molecules.
Clinical or Translational Implications
The observed patterns of cell-cell interactions, particularly the differential engagement of TGF-beta and EGFR signaling in the primary tumor, present several clinical and translational opportunities:
- Therapeutic Target Prioritization:
- TGF-beta Pathway: The widespread and enhanced TGF-beta signaling within the primary tumor microenvironment, especially involving Aneuploid Epi and Fibroblasts, positions this pathway as a prime therapeutic target in breast cancer. Inhibitors of TGF-beta signaling, or agents targeting its activation via integrins (e.g., integrin_avB6_complex), could disrupt tumor progression, reduce fibrosis, and potentially enhance anti-tumor immune responses https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900010/.
- EGFR Pathway: While EGFR inhibitors are already a cornerstone of cancer therapy for specific indications, the observed interactions (e.g., involving Endothelial cells in the tumor) suggest that targeting EGFR in the context of the TME, beyond just tumor cells, could have additional benefits, for example, by impacting angiogenesis or stromal support https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449552/.
- Biomarker Discovery and Patient Stratification:
- Specific ligand-receptor pairs or cell-cell interaction patterns, such as the TGFB1-TGFbeta_receptor1/2 interactions between Aneuploid Epi and Fibroblasts, or the presence of TGFB1_integrin_avB6_complex interactions, could serve as prognostic or predictive biomarkers for breast cancer patients. Identifying patients with highly active integrin-mediated TGF-beta activation could stratify them for specific therapeutic approaches.
- Rational Combination Therapies:
- Given the immunosuppressive role of TGF-beta, combining TGF-beta pathway inhibitors with immune checkpoint blockade (e.g., anti-PD-1/PD-L1) could be a synergistic strategy to overcome resistance to immunotherapy in breast cancer. Disrupting the TME by targeting stromal interactions could sensitize tumors to existing treatments.
- Experimental Validation:
- These findings warrant further experimental validation using *in vitro* co-culture models of specific cell types identified (e.g., tumor epithelial cells and fibroblasts) or *in vivo* models to confirm the functional significance of these predicted interactions. Targeting these interactions in preclinical models could assess their therapeutic potential.
14. Condition-Specific Cell-Cell Interaction Patterns in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates statistically significant differences in cell-cell interactions (CCI) between 'normal' and 'primary_tumor' conditions in human breast tissue, focusing on interactions involving T cells, Myeloid cells, Stromal cells (Fibroblast, Smooth muscle cell), Endothelial cells, and Mast cells. The results are visualized as a dot plot, highlighting the top 25 most significant differential interactions for each condition.
Visual Summary
The dot plot effectively illustrates distinct patterns of cell-cell communication between normal and primary tumor breast tissue samples.
- Differential Interaction Profiles: The plot is clearly divided into two major sections along the x-axis, representing interactions enriched in 'normal' samples and those enriched in 'primary_tumor' samples. This indicates a significant shift in cell-cell communication landscape during tumorigenesis.
- Normal Condition Interactions: Samples from the 'normal' condition (top-left blue box) exhibit a strong presence of interactions involving various growth factors, chemokines, and immune-related molecules such as ProstaglandinE2, SIRPA-CD47, CCL2-ACKR1, and TNFSF10. These interactions often involve Epithelial (Epi), Endothelial (Endo), Fibroblast (Fib), and ILC (Innate Lymphoid Cell) cell types. Dot sizes are large, and colors are dark red, indicating high significance and strong interaction strength for these pairs within normal samples.
- Primary Tumor Condition Interactions: In contrast, samples from the 'primary_tumor' condition (bottom-right blue box) are characterized by a predominant signature of interactions centered around Extracellular Matrix (ECM) components and their receptors. Specifically, there is a strong enrichment of interactions between various collagens (COL6A1, COL6A2, COL6A3, COL18A1) and fibronectin (FN1) with multiple integrin subunits (e.g., integrin_a1b1, integrin_a2b1, integrin_a3b1, integrin_avb5, integrin_a5b1). These interactions are primarily observed between Fibroblast, Epithelial (including Aneuploid Epithelial cells), Endothelial, and Smooth Muscle Cell types. Similar to the normal group, these tumor-specific interactions show large dot sizes and dark red colors, signifying high statistical significance and strong interaction levels within tumor samples.
- Ploidy Information: Some interaction labels specifically denote the ploidy status of epithelial cells (e.g., Epi (Diploid) or Epi (Aneuploid)). In the 'normal' context, both diploid and aneuploid epithelial cells participate in certain interactions. Critically, several collagen-integrin interactions in the 'primary_tumor' context involve 'Epi (Aneuploid)' cells, suggesting that the malignant (aneuploid) epithelial cells are active participants in these altered ECM interactions.
Biological Interpretation
The contrasting CCI profiles underscore fundamental biological differences between healthy and cancerous breast tissue microenvironments.
- Normal Tissue Homeostasis and Immune Surveillance: The enriched interactions in normal tissue suggest a microenvironment engaged in tissue maintenance, localized immune regulation, and inflammation.
- ProstaglandinE2 (PGE2) signaling via PTGER3/4: PGE2 is a lipid mediator involved in inflammation, immune modulation, and tissue repair. Its interactions with various cell types (Epithelial, Endothelial, Fibroblast, ILC) likely contribute to maintaining tissue homeostasis and regulating local immune responses in normal breast tissue [1].
- SIRPA-CD47 axis: This interaction is known as a "don't eat me" signal, critical for preventing phagocytosis of healthy cells by myeloid cells. Its presence in normal tissue suggests active mechanisms to maintain self-tolerance and immune evasion from innate immune cells [2].
- CCL2-ACKR1 (DARC): CCL2 is a key chemokine that recruits monocytes/macrophages. ACKR1 (DARC) acts as a chemokine scavenger, regulating chemokine availability and leukocyte trafficking [3]. This interaction likely controls local inflammatory cell recruitment and resolution in normal tissue.
- TNFSF10 (TRAIL)-TNFRSF10A/B: TRAIL signaling primarily induces apoptosis in cancer cells but can also regulate immune cell function and survival in healthy cells. Its presence may contribute to maintaining cellular turnover and immune balance [4].
- Tumor Microenvironment Remodeling and Malignant Progression: The pronounced shift towards extensive ECM-integrin interactions in primary tumors is a hallmark of cancer progression.
- Collagen-Integrin interactions (COL6A1/A2/A3/18A1 with various Integrins): Collagens are major structural components of the ECM. In cancer, altered collagen deposition and cross-linking significantly impact tumor stiffness, cell migration, invasion, and metastasis [5]. Integrins are crucial cell surface receptors mediating cell-ECM adhesion and signaling. The extensive engagement of multiple collagen-integrin pairs suggests:
- ECM Remodeling: Tumor cells, fibroblasts, and endothelial cells actively remodel the ECM, creating a pro-tumorigenic niche that facilitates tumor growth and invasion.
- Cell Adhesion and Migration: Increased integrin signaling promotes tumor cell adhesion, survival, and migration, contributing to invasive phenotypes.
- Angiogenesis: Endothelial cells interacting with ECM components via integrins are critical for pathological angiogenesis, supporting tumor blood supply.
- Fibronectin (FN1)-Integrin interactions: Fibronectin is another key ECM glycoprotein involved in cell adhesion, migration, and differentiation. Its interactions with integrins are highly upregulated in many cancers, promoting tumor cell invasion, metastasis, and resistance to therapy [6].
- Involvement of Aneuploid Epithelial Cells: The observation that 'Epi (Aneuploid)' cells, likely the malignant epithelial cells, are prominently involved in these ECM-integrin interactions highlights their active role in shaping and responding to the altered tumor microenvironment. This suggests a direct contribution of tumor cells to ECM remodeling and their reliance on these interactions for survival and progression.
Clinical or Translational Implications
These findings point to specific cell-cell interaction axes that could serve as potential therapeutic targets or prognostic markers in breast cancer.
- ECM-Integrin Axis as Therapeutic Targets: The widespread upregulation of collagen-integrin and fibronectin-integrin interactions in primary tumors strongly suggests that targeting these pathways could disrupt crucial aspects of tumor progression, including invasion, metastasis, and angiogenesis.
- Integrin Inhibitors: Therapies targeting specific integrins (e.g., αVβ3, α5β1) have been explored in various cancers to inhibit angiogenesis and metastasis [7]. The identified specific integrin pairs (e.g., α1β1, α2β1, α3β1, αVβ5, α5β1) warrant further investigation as potential candidates for breast cancer-specific integrin blockade.
- ECM Modulators: Strategies aimed at normalizing the tumor ECM or inhibiting specific collagen synthesis/modification could also interfere with tumor cell survival and invasion.
- Biomarker Potential: The differential expression of specific CCI pairs between normal and tumor conditions could potentially be developed as diagnostic or prognostic biomarkers for breast cancer, reflecting the aggressiveness of the tumor microenvironment.
- Understanding Tumor-Stroma Crosstalk: The prominence of interactions between Fibroblasts, Epithelial cells, and Endothelial cells in the tumor microenvironment underscores the critical role of tumor-stroma crosstalk. Targeting this communication, rather than just the tumor cells themselves, could be a more effective therapeutic strategy.
References
- Prostaglandin E2: PubMed search for "Prostaglandin E2 cancer immune regulation" https://pubmed.ncbi.nlm.nih.gov/?term=Prostaglandin+E2+cancer+immune+regulation
- SIRPA-CD47: GeneCards entry for CD47 https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD47
- CCL2-ACKR1: PubMed search for "CCL2 ACKR1 cancer" https://pubmed.ncbi.nlm.nih.gov/?term=CCL2+ACKR1+cancer
- TNFSF10 (TRAIL): UniProt entry for TRAIL https://www.uniprot.org/uniprotkb/O14790/entry
- Collagen in Cancer: PubMed search for "collagen tumor microenvironment" https://pubmed.ncbi.nlm.nih.gov/?term=collagen+tumor+microenvironment
- Fibronectin in Cancer: GeneCards entry for FN1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=FN1
- Integrin Inhibitors: PubMed search for "integrin inhibitors cancer therapy" https://pubmed.ncbi.nlm.nih.gov/?term=integrin+inhibitors+cancer+therapy
15. Epithelial Cell Condition-Specific Surfaceome Markers in Breast Cancer
[Analysis Visualization Results]...
Analysis Overview
This analysis investigates condition-specific surfaceome markers within Epithelial cells, identified as the tumor-origin cell type, from single-cell RNA-seq data of human breast tissue. The aim is to distinguish between normal and primary tumor conditions based on surface protein expression patterns. The visualization presents genes expressed on the cell surface, showing both the mean expression level and the fraction of cells expressing each gene across different patient samples, grouped by condition (normal vs. primary tumor) and ploidy status (diploid vs. likely aneuploid).
Visual Summary
The dot plot effectively illustrates clear differences in surfaceome marker expression between normal and primary tumor epithelial cells:
- Normal-Associated Markers: Genes such as *ITGA2*, *SLC39A14*, *EVA1C*, and *GLIPR1* show prominently higher mean expression (darker red dots) and are expressed in a larger fraction of cells (larger dot sizes) within the normal epithelial cell samples. These markers are generally downregulated or absent in the primary tumor samples.
- Primary Tumor-Associated Markers: A distinct cluster of markers is highly and consistently expressed in primary tumor epithelial cells. Key examples include *EGFR*, *NECTIN2*, *TSPAN13*, *SLC39A6*, *CLDN3*, *EFNA1*, *TMEM106B*, *EMP2*, *MUC1*, *ERBB3*, *NECTIN4*, *ADAM15*, *CA12*, and *PRLR*. These genes exhibit strong mean expression and a high fraction of expressing cells across most primary tumor samples, particularly those from non-diploid patients. Conversely, their expression is minimal or absent in normal samples.
- Ploidy Correlation: A notable pattern emerges regarding ploidy status. Samples annotated as "Diploid Patient" predominantly show a normal-like marker profile. In contrast, "Patient" samples (inferred to be aneuploid based on the data context) largely belong to the primary tumor group and display strong expression of the tumor-associated markers. This suggests a strong association between aneuploidy and the malignant epithelial cell phenotype characterized by this distinct surfaceome signature.
- Patient Heterogeneity: While distinct condition-specific patterns are evident, some heterogeneity in marker expression and prevalence exists among individual patient samples within both the normal and tumor groups.
Biological Interpretation
The identified surfaceome markers provide crucial insights into the biological changes occurring in breast epithelial cells during tumorigenesis.
- Normal Epithelial Homeostasis: The markers enriched in normal epithelial cells, such as *ITGA2* (Integrin Alpha-2, involved in cell adhesion) and *GLIPR1* (often a tumor suppressor), suggest a profile conducive to maintaining normal tissue architecture and function. Their reduction in tumor cells implies a disruption of these homeostatic processes.
- Oncogenic Signaling and Tumor Progression: The strong upregulation of a diverse set of surface molecules in primary tumor epithelial cells points to multiple pathways driving malignancy:
- Growth Factor Signaling: EGFR (Epidermal Growth Factor Receptor) and ERBB3 (HER3) are well-known receptor tyrosine kinases that drive proliferation, survival, and metastasis in breast cancer. Their co-expression highlights the activation of critical pro-oncogenic pathways. GeneCards: EGFR, GeneCards: ERBB3
- Altered Cell Adhesion and Invasion: NECTIN2, NECTIN4, CLDN3 (Claudin-3), and ADAM15 (ADAM Metallopeptidase Domain 15) are involved in cell-cell adhesion and extracellular matrix remodeling. Nectin-4, in particular, is frequently overexpressed in breast cancer and contributes to increased invasiveness. PubMed: Nectin-4 in cancer progression Dysregulation of these molecules facilitates tumor cell detachment, migration, and invasion.
- Metabolic Reprogramming and Microenvironment Interaction: CA12 (Carbonic Anhydrase XII) plays a role in pH regulation, often upregulated in hypoxic tumor microenvironments, which can contribute to an acidic environment promoting tumor growth and invasion. GeneCards: CA12
- Tumor-Associated Antigens: MUC1 (Mucin 1) is a classic tumor-associated antigen, highly expressed in various adenocarcinomas including breast cancer, and involved in immune evasion and cell signaling. GeneCards: MUC1
- Tetraspanins: TSPAN13 and TSPAN15 belong to the tetraspanin family, which form molecular platforms on the cell surface influencing various processes including cell motility, proliferation, and immune responses, often implicated in cancer progression.
- Aneuploidy as a Driver: The strong correlation between likely aneuploid samples and the tumor-specific surfaceome underscores the role of genomic instability in shaping the malignant phenotype of breast epithelial cells.
Clinical or Translational Implications
The identified condition-specific surfaceome markers in breast epithelial cells hold significant promise for clinical applications. Given their surface localization, these proteins are highly accessible for diagnostic, prognostic, and therapeutic interventions.
Biomarker Development
- Diagnostic Markers: The distinct expression of markers like *EGFR*, *NECTIN4*, and *MUC1* in tumor cells could be utilized for non-invasive early detection using liquid biopsies (e.g., detection of circulating tumor cells or extracellular vesicles).
- Prognostic Markers: The presence or absence of specific markers could help predict disease aggressiveness, recurrence risk, or response to therapy, guiding personalized treatment strategies.
- Therapeutic Targets: The tumor-specific surface proteins are excellent candidates for targeted therapies:
- Antibody-Drug Conjugates (ADCs): Many upregulated surface proteins (e.g., EGFR, ERBB3, NECTIN4, MUC1, BST2) could serve as anchors for ADCs, delivering cytotoxic drugs directly to cancer cells while sparing healthy tissues. This approach has shown success with other targets in breast cancer (e.g., HER2-targeting ADCs). PubMed search: Antibody-drug conjugates breast cancer
- Monoclonal Antibodies: Blocking antibodies against critical receptors like EGFR or ERBB3 could directly inhibit pro-tumorigenic signaling pathways.
- Immunotherapy: Markers such as MUC1, which are overexpressed on tumor cells, could be explored as targets for CAR T-cell therapy or other immunotherapeutic approaches, aiming to enhance the immune system's ability to recognize and destroy cancer cells. PubMed search: CAR T cell therapy MUC1 breast cancer
This analysis provides a robust foundation for further functional studies and validation of these promising surfaceome markers as potential diagnostic tools and therapeutic targets in breast cancer.
16. Macrophage Condition-Specific Surfaceome Markers in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies and visualizes condition-specific surfaceome markers for Macrophage cells in breast tissue, comparing normal tissue with primary tumors. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across individual patient samples, grouped by condition. The focus is on surfaceome proteins, which are particularly relevant for cell-surface-mediated interactions and potential therapeutic targeting.
Visual Summary
The dot plot effectively distinguishes macrophage surfaceome profiles between normal and primary tumor conditions, as well as highlighting heterogeneity within primary tumors.
- Normal Condition Profile: Only one normal sample (Patient_4_4B146L_RNA) is displayed. Macrophages in this sample show high expression and prevalence of markers such as CD163, FPR1, C3AR1, and CCR7. These genes are largely absent or expressed at very low levels in the primary tumor samples.
- Primary Tumor Condition Profile: A distinct set of surfaceome markers is highly expressed and prevalent across multiple primary tumor samples. Key markers include EREG, HLA-DMA, TMEM123, ITGB8, CD55, CXCR4, LAMP2, CD109, MPZL1, IL6R, SLC1A3, ITGAV, TPRA1, HLA-F, SLC44A1, TFPI, IL13RA1, AQP9, FURIN, MET, GINM1, and TNFSF13B.
- Heterogeneity within Primary Tumors: While many genes show general upregulation in tumors, there is notable variability in expression levels and prevalence among individual primary tumor samples. For instance, samples like Patient_9_3B3E9L_RNA and Patient_5_35A4AL_RNA exhibit particularly strong and broad expression of several tumor-associated markers, whereas other samples show more restricted patterns.
Biological Interpretation
The observed differential expression of surfaceome markers points to a significant phenotypic shift in macrophages within the primary breast tumor microenvironment compared to normal breast tissue.
- Normal Tissue Macrophages: The high expression of CD163 suggests that macrophages in normal breast tissue may lean towards an M2-like phenotype, commonly associated with immune regulation, tissue repair, and scavenger functions, which is typical for resident tissue macrophages. FPR1 is involved in chemotaxis, and C3AR1 (complement C3a receptor) indicates responsiveness to complement components, crucial for innate immune sensing. CCR7 is known for guiding immune cell migration.
- Tumor-Associated Macrophages (TAMs) in Primary Tumors: The distinct set of markers in primary tumors reflects the dynamic and often pro-tumorigenic role of TAMs in breast cancer.
- Pro-tumorigenic Functions: Markers such as EREG (Epiregulin) GeneCards: EREG, CXCR4 GeneCards: CXCR4, and MET GeneCards: MET are frequently associated with tumor cell proliferation, survival, angiogenesis, and metastasis. Macrophages expressing these can contribute to an immunosuppressive and pro-metastatic tumor microenvironment.
- Immune Modulation and Interaction: Upregulation of HLA-DMA and HLA-F (MHC class I/II related molecules) suggests altered antigen presentation capabilities or immune signaling within TAMs. IL6R (Interleukin-6 Receptor) indicates responsiveness to IL-6, a cytokine that promotes inflammation and tumor progression PubMed search: IL6R cancer.
- Adhesion and Migration: Integrins like ITGB8 and ITGAV are crucial for cell-extracellular matrix interactions and cell migration, which are vital for TAM recruitment and function within the complex tumor stroma.
- Other Roles: Genes like TFPI (Tissue Factor Pathway Inhibitor) are involved in coagulation but also linked to angiogenesis and tumor growth, while TNFSF13B (BAFF) plays a role in B cell survival and has been implicated in immune evasion mechanisms in cancer.
The marked contrast between the normal and tumor-associated macrophage surfaceome profiles highlights the profound reprogramming macrophages undergo in the presence of cancer, adapting functions that often support tumor progression.
Clinical or Translational Implications
The identification of condition-specific surfaceome markers on macrophages in breast cancer has several important clinical and translational implications:
- Biomarker Discovery: The distinct surface marker profiles (e.g., high CD163 in normal vs. EREG, CXCR4, MET in primary tumor) could serve as valuable diagnostic or prognostic biomarkers for breast cancer, potentially aiding in distinguishing tumor-infiltrating macrophages from resident macrophages in non-malignant tissue.
- Therapeutic Targets: Surfaceome markers that are highly expressed in TAMs but absent or low in normal macrophages represent promising therapeutic targets.
- For example, CXCR4 is a known target for blocking cancer cell metastasis and immune cell trafficking. Targeting CXCR4 on TAMs could inhibit their recruitment or function within the tumor.
- MET signaling is a therapeutic target in various cancers, and inhibiting MET on TAMs could impede their pro-tumorigenic activities.
- IL6R could be targeted to block IL-6 mediated inflammatory and pro-tumorigenic signaling pathways involving macrophages.
These targets offer avenues for developing novel macrophage-targeted immunotherapies, such as antibodies or small molecules, to re-educate pro-tumorigenic macrophages or deplete them from the tumor microenvironment.
- Patient Stratification: The observed inter-patient heterogeneity in TAM surface marker expression suggests that patients might respond differently to macrophage-targeted therapies. Stratifying patients based on their TAM marker profiles could enable more personalized and effective treatment strategies.
- Experimental Validation: These identified markers provide concrete targets for further experimental validation using techniques like flow cytometry or immunohistochemistry to confirm protein expression and localization in breast cancer tissues, and to investigate their functional roles in TAM biology and tumor progression.
17. Fibroblast Condition-Specific Surfaceome Markers in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis identifies condition-specific surfaceome markers for Fibroblasts, comparing normal breast tissue with primary breast tumor samples. The dot plot visualizes the expression of these markers across individual patient samples, indicating both the mean expression level (color intensity) and the fraction of cells expressing the marker (dot size) within the Fibroblast population. This approach aims to uncover surface-accessible proteins that distinguish tumor-associated fibroblasts from those in normal tissue.
Visual Summary
The dot plot clearly segregates fibroblast populations based on their gene expression profiles, aligning with the "normal" and "primary_tumor" conditions.
- Normal Fibroblasts (top samples): Patients such as Patient_4_B146L_RNA, Patient_1_49758L_RNA, Patient_2_49CFCL_RNA, and Patient_3_4AF75L_RNA show very low to negligible expression (small, light-colored dots or no dots) for the majority of the plotted surfaceome markers. This indicates a relatively quiescent or non-activated state for these fibroblasts compared to tumor samples.
- Primary Tumor Fibroblasts (bottom samples): A striking pattern emerges in samples from patients like Patient_8_3821AL_RNA, Patient_14_43E7CL_RNA, Patient_14_43E7BL_RNA, Patient_12_44F0AL_RNA, Patient_15_45CB0L_RNA, Patient_6_4C2E5L_RNA, Patient_9_3B3E9L_RNA, Patient_13_3D388L_RNA, Patient_7_35EE8L_RNA, Patient_10_3C7D1L_RNA, Patient_5_35A4AL_RNA, and Patient_11_3FCDEL_RNA. These samples exhibit high expression (dark red dots) and a high fraction of expressing cells (large dots) for numerous genes. This robust upregulation is indicative of a profound phenotypic shift in fibroblasts within the tumor microenvironment.
- Key Tumor-Associated Fibroblast Markers: Several genes stand out as highly expressed and prevalent in primary tumor fibroblasts. These include FAP, CD276, PMEPA1, MMP14, GPNMB, MXRA8, ICAM1, LY6E, ITGB5, IFNGR2, THY1 (CD90), NRP2, SCARB2, PTTG1IP, TMEM123, MYADM, DDR2, TMEM158, IFNA1, ABCA1, GAS1, TSPAN4, SGCB, CD9, ANTXR1, PLXDC2, EDNRB, and EDNRA.
- Cell Counts per Patient: The bar chart on the right indicates the number of fibroblast cells identified per patient sample, ranging from 399 to 3009 cells. This provides context on the cellular representation from each individual.
Biological Interpretation
The observed upregulation of specific surfaceome markers in primary tumor fibroblasts points to their transformation into Cancer-Associated Fibroblasts (CAFs), a critical component of the tumor microenvironment (TME). CAFs play diverse roles in promoting tumor growth, invasion, metastasis, angiogenesis, and immune suppression.
Notable markers and their biological roles:
- FAP (Fibroblast Activation Protein): A well-established marker of activated fibroblasts in various cancers, including breast cancer. FAP-expressing CAFs contribute to extracellular matrix (ECM) remodeling, creating a pro-tumorigenic niche, and can suppress anti-tumor immunity. GeneCards: FAP
- CD276 (B7-H3): An immune checkpoint molecule belonging to the B7 family, often overexpressed in various cancers and on CAFs. It can suppress anti-tumor T-cell responses, contributing to immune evasion. GeneCards: CD276
- MMP14 (Matrix Metalloproteinase 14): A membrane-anchored metalloproteinase crucial for degrading ECM components, facilitating tumor cell invasion and metastasis, and promoting angiogenesis.
- GPNMB (Glycoprotein Non-metastatic Melanoma Protein B): Implicated in tumor progression, invasion, and metastasis in several cancers, including breast cancer. It can promote cell migration and survival.
- EDNRB (Endothelin Receptor Type B) and EDNRA (Endothelin Receptor Type A): Receptors for endothelin peptides, involved in various physiological processes including vasoconstriction and cell proliferation. Their dysregulation and activation of endothelin signaling pathways are frequently observed in cancer, contributing to tumor growth and progression in a paracrine fashion with tumor cells.
- ICAM1 (Intercellular Adhesion Molecule 1): Involved in cell-cell adhesion, immune cell trafficking, and inflammation. Its upregulation on CAFs might influence the recruitment and interaction of immune cells within the TME.
- DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2): A receptor tyrosine kinase that binds to collagen, modulating cell-ECM interactions, cell proliferation, and migration, which are all critical for CAF function.
- THY1 (CD90): A glycosylphosphatidylinositol (GPI)-anchored protein expressed on various cell types, including subsets of fibroblasts and stem cells. Its role in CAFs is complex but often associated with a pro-tumorigenic phenotype and resistance to therapy.
- The collective upregulation of these surface markers highlights a robust "activated" phenotype of fibroblasts in the primary tumor microenvironment, indicating their active participation in disease progression.
Clinical or Translational Implications
The identification of these highly expressed surfaceome markers on breast cancer-associated fibroblasts holds significant clinical and translational potential:
- Diagnostic/Prognostic Biomarkers: The unique surface signature of tumor-associated fibroblasts could serve as diagnostic markers for breast cancer or prognostic indicators for disease aggressiveness and patient outcome.
- Therapeutic Targets: Since these markers are located on the cell surface, they represent accessible targets for novel therapeutic strategies. For instance, antibodies targeting FAP or CD276 are already being investigated in cancer therapy to specifically deplete CAFs or block their pro-tumorigenic functions. PubMed Search: FAP breast cancer therapy PubMed Search: B7-H3 breast cancer therapy
- Patient Stratification: Understanding the specific CAF subtypes defined by these markers could lead to improved patient stratification for targeted therapies, allowing for more personalized treatment approaches.
- Experimental Validation: These findings provide strong candidates for further experimental validation using techniques such as immunohistochemistry (IHC) or multiplex immunofluorescence on patient tissue samples to confirm protein expression and localization, or in vitro/in vivo functional assays to elucidate their precise roles in breast cancer progression and response to therapy.
18. Cell-Type-Specific Surfaceome Marker Discovery in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify condition-specific surfaceome markers for T cell CD4+ populations and other cell types within breast tissue from single-cell RNA sequencing data. The plot_markers_and_expression_dot tool was used, configured to find up to 50 surfaceome markers. While the user query specifically asked for "condition-specific" markers for T cell CD4+, the generated dot plot displays markers that are highly *cell-type-specific* across various immune and stromal cell subsets (e.g., Endothelial cells, Fibroblasts, Macrophages, different T cell subsets, etc.). This suggests the marker discovery focused on distinguishing cell types from each other rather than comparing conditions (primary tumor vs. normal) within a single cell type. The plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for each cell type.
Visual Summary
The dot plot effectively illustrates the distinct expression patterns of various surfaceome-enriched genes across 25 different cell subsets found in the breast tissue.
- Cell Type Specificity: The plot is organized with cell types on the y-axis and marker genes on the x-axis. Clusters of highly expressed genes, often enclosed by red boxes, clearly demarcate markers characteristic of specific cell types (e.g., Fibroblast, Luminal epithelial cell, T cell (Cytotoxic), T cell (Treg)). This block-like pattern confirms the successful identification of cell-type-specific markers.
- Expression Levels and Prevalence: The color intensity of each dot represents the mean expression level of a gene within a given cell group, with darker red indicating higher expression. The size of the dot indicates the fraction of cells in that group expressing the gene (non-zero expression). This allows for quick identification of highly expressed and widely expressed markers within a population.
- Cell Type Abundance: The bar chart on the right indicates the relative abundance of each cell type in the dataset, with Fibroblasts (24176 cells) and Luminal epithelial cells (23141 cells) being the most abundant.
- Identified Markers: The analysis successfully identified numerous markers, including those associated with different T cell subsets (e.g., Tfh, Th1, Th17, Th2, Th22, Treg), which aligns with the user's primary interest in T cell CD4+ markers.
Biological Interpretation
The analysis revealed distinct surfaceome marker profiles for various cell types in the breast microenvironment, including several CD4+ T cell subsets.
- T cell (Treg) Markers: This subset is characterized by markers such as CTLA4 and TNFRSF18 (GITR), both crucial immune checkpoints/co-stimulatory molecules involved in Treg function and immune suppression. Notably, FOXP3, an intracellular master transcription factor for Treg development and function, is also highly expressed here. Its presence despite the surfaceome_only parameter might indicate a broad interpretation of "surfaceome-associated" genes or the inclusion of canonical intracellular markers for identification.
- *Reference for CTLA4*: GeneCards: CTLA4
- *Reference for TNFRSF18 (GITR)*: GeneCards: TNFRSF18
- T cell (Tfh) Markers: Markers like PDCD1 (PD-1) and CD84 are observed. PD-1 is a key inhibitory receptor expressed on activated T cells, including Tfh cells, where it regulates B cell help. CD84 (SLAMF5) is part of the SLAM family of receptors involved in immune cell activation and adhesion.
- *Reference for PDCD1 (PD-1)*: GeneCards: PDCD1
- T cell (Naive) Markers: SELL (CD62L), an adhesion molecule involved in lymphocyte homing to lymph nodes, is a prominent marker for naive T cells.
- T cell (Th1) Markers: Markers like IFNGR1, IFNGR2 (interferon-gamma receptors), and CXCR3 are highly expressed. STAT1, an intracellular transcription factor critical for Th1 differentiation and IFN-gamma signaling, is also shown.
- T cell (Th17) Markers: IL18R1 is highlighted. RORC, the master transcription factor for Th17 cells, is also present in the list, again suggesting a broader inclusion beyond strict surfaceome for canonical cell type identifiers.
- T cell (Th2) Markers: GATA3, the master transcription factor for Th2 cells, is a prominent marker.
- T cell (Cytotoxic) Markers: While the user query focused on CD4+ T cells, the plot also identified markers for T cell (Cytotoxic) populations, predominantly CD8A, CD8B (components of the CD8 co-receptor, indicating CD8+ T cells), GZMB (Granzyme B), and LAG3. GZMB is an intracellular serine protease essential for cytotoxic function, again an intracellular marker. LAG3 is an immune checkpoint molecule.
- *Reference for GZMB*: GeneCards: GZMB
Beyond T cells, the plot also effectively identified markers for other key cell types:
- Fibroblasts: Rich in extracellular matrix components and associated proteins like COL1A1, COL1A2, COL3A1 (collagens), DCN (decorin), LUM (lumican), and FAP (fibroblast activation protein). The presence of ACTA2 (alpha-SMA) suggests the presence of myofibroblasts.
- Epithelial Cells (Luminal and Mammary): Characterized by keratins (KRT7, KRT8, KRT18, KRT19) and CDH1 (E-cadherin), indicative of their epithelial origin and adhesive properties. MUC1 is also a key epithelial marker.
- Endothelial Cells: Markers such as ANGPT2, ESM1, ACKR1, CDH5 reflect their vascular functions.
- Macrophages: CD74 and CD68 are commonly observed macrophage markers.
- Mast Cells: Distinctly marked by KIT (CD117), TPSAB1, and TPSB2, consistent with their immunological role.
- *Reference for KIT (CD117)*: GeneCards: KIT
The inclusion of several intracellular markers (e.g., FOXP3, STAT1, GATA3, RORC, GZMB) in a "surfaceome only" analysis suggests that either the definition of surfaceome was broad or these highly canonical intracellular markers were specifically allowed in the marker finding process to ensure robust cell type identification.
Clinical or Translational Implications
The identification of cell-type-specific surfaceome markers has significant implications for both understanding breast biology and developing clinical strategies.
- Biomarker Discovery and Diagnostic Potential: The distinct surface marker profiles for various immune and stromal cells, especially T cell subsets, could serve as robust biomarkers for characterizing the cellular composition of breast tumors and normal tissue. These markers could be used in diagnostic panels via flow cytometry or immunohistochemistry to assess tumor immune infiltration and predict patient response to therapy.
- Therapeutic Target Identification: Surface proteins are excellent candidates for therapeutic intervention as they are accessible to antibodies and other targeted modalities.
- Immune Checkpoint Modulators: Markers like CTLA4 (Treg) and PDCD1 (PD-1) (Tfh/activated T cells) are established targets in cancer immunotherapy. The precise identification of their expression on specific T cell subsets can refine strategies for targeting these pathways in breast cancer.
- Co-stimulatory/Co-inhibitory Receptors: TNFRSF18 (GITR) on Tregs represents a potential target for immune activation. Modulating GITR can enhance anti-tumor immunity by inhibiting Treg function or activating effector T cells.
- Cell Depletion/Targeting: Highly specific surface markers (e.g., FAP for activated fibroblasts, KIT for mast cells) could be explored for targeted depletion or modulation of specific stromal or immune cell populations that promote tumor growth or resistance.
- Experimental Validation and Translational Research: The identified surface markers provide a valuable starting point for experimental validation. Researchers can use antibodies against these markers in techniques such as:
- Flow Cytometry: To accurately quantify and sort specific T cell subsets from patient samples.
- Immunohistochemistry/Immunofluorescence: To visualize the spatial distribution and abundance of these cell types within the breast tissue microenvironment.
- In vivo studies: To test the efficacy of novel therapeutic agents targeting these markers in preclinical models.
- Limitations and Future Directions: While this analysis provides valuable cell-type-specific markers, the initial query for "condition-specific" markers (primary tumor vs. normal) was not directly addressed in this plot. A subsequent differential expression analysis *within* each T cell subset, comparing primary tumor vs. normal conditions, would be necessary to identify markers that specifically distinguish T cell CD4+ states in disease versus healthy states. Such an analysis would provide more direct insight into disease-associated changes and potential therapeutic targets unique to the tumor microenvironment.
19. Differential Expression of Cell Cycle-Related Genes in Breast Cancer Epithelial Cells: YWHAZ Upregulation
[Analysis Visualization Results]...
Analysis Overview
This analysis aimed to identify and visualize statistically significant expression differences of selected cell cycle-related genes within specific cell types (Epithelial cell, Fibroblast, Macrophage) between 'primary_tumor' and 'normal' breast tissue conditions. The provided boxplot specifically illustrates the differential expression of the YWHAZ gene in Epithelial cells, which are the tumor-origin cells in breast tissue.
Visual Summary
The boxplot for the gene YWHAZ in Epithelial cells reveals a marked difference in its expression levels between the two conditions:
- Elevated Expression in Tumor: YWHAZ expression is substantially higher in Epithelial cells derived from 'primary_tumor' samples compared to those from 'normal' samples. The median expression in primary tumors is visibly greater, with the entire distribution of sample means shifted upwards.
- Statistical Significance: The observed difference is highly statistically significant, as indicated by a p-value less than or equal to 0.001 (p ≤ 0.001).
- Data Distribution: Each black dot represents the mean gene expression for YWHAZ in Epithelial cells from an individual sample, demonstrating consistent upregulation across most tumor samples compared to normal samples, despite some variability within each group.
Biological Interpretation
The significant upregulation of YWHAZ (Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) in Epithelial cells within the primary tumor environment is a key finding, especially considering that Epithelial cells are the cells of tumor origin in breast cancer.
- Role in Cell Cycle and Cancer: YWHAZ is a member of the 14-3-3 protein family, which plays diverse and critical roles in regulating cellular processes such as cell cycle progression, cell growth, signal transduction, and apoptosis. These proteins act by binding to phosphorylated target proteins, thereby modulating their activity, stability, or subcellular localization [GeneCards: GeneCards].
- Implication in Breast Cancer: The increased expression of YWHAZ in tumor epithelial cells suggests its potential involvement in driving tumorigenesis. In various cancers, including breast cancer, YWHAZ overexpression has been linked to enhanced cell proliferation, survival, invasion, and resistance to apoptotic signals, characteristics that are central to cancer progression. Its function in modulating cell cycle checkpoints and pathways likely contributes to the uncontrolled growth commonly observed in malignant epithelial cells.
Clinical or Translational Implications
- Biomarker Potential: Given its highly significant upregulation in cancerous epithelial cells, YWHAZ could serve as a potential diagnostic or prognostic biomarker for breast cancer, particularly for assessing the proliferative capacity of the tumor.
- Therapeutic Target: The prominent role of YWHAZ in supporting tumor cell growth and survival, as indicated by its elevated expression in primary tumor epithelial cells, suggests it could be a promising therapeutic target. Inhibiting YWHAZ activity might interfere with critical cell cycle regulation and survival pathways, potentially curbing tumor growth or enhancing the effectiveness of existing cancer treatments [PubMed search for "YWHAZ breast cancer therapeutic target": PubMed Search].
- Further Research: While this analysis highlights YWHAZ's potential, comprehensive functional studies are warranted to fully elucidate its precise mechanisms in breast cancer epithelial cells and to validate its clinical utility as a biomarker or therapeutic target.
20. Epithelial Cell Gene Ontology (GSA) Analysis: Condition and Ploidy-Specific Pathway Enrichment in Breast Tissue
[Analysis Visualization Results]...
Analysis Overview
This analysis utilizes Gene Ontology (GSA) to identify enriched biological pathways and processes in epithelial cells within the provided single-cell RNA-seq dataset. The goal is to understand how pathway activity differs across various cellular states, specifically comparing diploid versus other epithelial cells, normal versus other epithelial cells, and primary tumor versus other epithelial cells. The results are visualized as bar plots, showing the statistical significance (-log(p-val) and -log(q-val)) of enriched terms.
Visual Summary
The visualizations present three bar plots, each detailing the most significantly enriched Gene Ontology (GO) terms and other pathway database terms (e.g., from KEGG) for epithelial cells under different comparison contexts:
- Diploid_vs_others: Pathways enriched in diploid epithelial cells compared to all other (presumably aneuploid) epithelial cells.
- normal_vs_others: Pathways enriched in normal epithelial cells compared to all other (presumably primary tumor) epithelial cells.
- primary_tumor_vs_others: Pathways enriched in primary tumor epithelial cells compared to all other (presumably normal) epithelial cells.
Each plot displays the top enriched "Term" on the y-axis, ranked by statistical significance, with corresponding -log(p-val) and -log(q-val) on the x-axis. A higher value indicates greater statistical significance. The primary_tumor_vs_others comparison shows the highest significance levels for enriched terms, followed by normal_vs_others, and then Diploid_vs_others.
Biological Interpretation
Diploid Epithelial Cells (vs. others)
Epithelial cells maintaining diploidy, often representing a more stable genomic state, exhibit enrichment in pathways that suggest a baseline of cellular function and interaction with the microenvironment:
- Immune and Viral Response Pathways: Several viral infection pathways (e.g., Coronavirus, Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus, Human T-cell leukemia virus 1, Human papillomavirus, Human cytomegalovirus, Herpes simplex virus 1, Hepatitis B) are highly enriched. This might indicate ongoing basal immune surveillance, past exposures, or common cellular responses to pathogens within a subset of epithelial cells.
- Cellular Stress and Turnover: Terms like Cellular senescence and p53 signaling pathway suggest mechanisms for regulating cell cycle, DNA damage response, and preventing uncontrolled proliferation. Phagosome enrichment could point to active waste removal or antigen presentation processes.
- Inflammatory and Signaling Pathways: Th17 differentiation, Allograft rejection, Graft-versus-host disease, Autoimmune thyroid disease, Th1 and Th2 differentiation, NF-kappa B signaling pathway, PI3K-Akt signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, and B cell receptor signaling pathway highlight the role of diploid epithelial cells in immune regulation and inflammatory responses. This suggests their active participation in or response to the immune microenvironment.
- Cellular Structure and Adhesion: Focal adhesion indicates maintenance of cell-matrix interactions, critical for tissue integrity.
- Ribosome: Enrichment of Ribosome suggests active protein synthesis, essential for basic cell functions.
Normal Epithelial Cells (vs. others)
Normal epithelial cells, when compared to other epithelial cells (likely predominantly tumor cells), show distinct pathway enrichments:
- Fundamental Cellular Machinery: High enrichment of Ribosome and Proteasome suggests robust protein synthesis and degradation machinery, essential for maintaining cellular homeostasis and healthy protein turnover. Ribosome biogenesis in eukaryotes further supports active cellular anabolism.
- Epithelial Integrity and Polarity: Pathways like Focal adhesion, Regulation of actin cytoskeleton, and Tight junction are critically important for maintaining the structural integrity, adhesion, and polarity characteristic of healthy epithelial tissue.
- Cellular Stress and Homeostasis: Protein processing in endoplasmic reticulum and Apoptosis indicate active mechanisms for protein quality control and regulated cell death, crucial for tissue maintenance.
- Unexpected Associations: A notable number of neurodegenerative disease pathways (Parkinson's disease, Amyotrophic lateral sclerosis, Pathways of neurodegeneration, Alzheimer's disease, Huntington's disease, Prion disease, Spinocerebellar ataxia) are significantly enriched. This could reflect shared molecular mechanisms of cellular stress, mitochondrial dysfunction, or protein aggregation that are active in normal epithelial cells, rather than implying actual neurological pathology.
- Signaling and Metabolic Baselines: PI3K-Akt signaling pathway and TNF signaling pathway represent fundamental pathways involved in cell survival, growth, and inflammation, operating at a baseline in normal cells.
Primary Tumor Epithelial Cells (vs. others)
Epithelial cells from primary tumors display a pronounced shift in their active pathways, reflecting cancer-associated biology:
- Altered Metabolism: Oxidative phosphorylation, Valine, leucine and isoleucine degradation, AMPK signaling pathway, Insulin signaling pathway, and Citrate cycle (TCA cycle) indicate a significant metabolic reprogramming in tumor cells, often characterized by altered energy production and nutrient utilization to support rapid growth and proliferation. Thermogenesis might point to altered mitochondrial activity.
- Protein Handling and Stress Response: Pathways like Protein processing in endoplasmic reticulum, Autophagy, Ubiquitin mediated proteolysis, and Lysosome are highly active. This suggests heightened cellular stress due to rapid proliferation, accumulation of misfolded proteins, and increased demand for recycling cellular components to fuel growth. Mitochondrial quality control (Mitophagy) is also enriched.
- Growth and Proliferation Signaling: mTOR signaling pathway, a key regulator of cell growth, proliferation, and metabolism, is significantly enriched, consistent with its known role in driving cancer progression.
- Cellular Adhesion (complex role): While tumor cells are often characterized by loss of adhesion, the enrichment of Tight junction and Adherens junction pathways might reflect specific tumor cell subsets, early stages of epithelial-mesenchymal transition, or adaptive mechanisms where these junctions are re-purposed for survival or invasion.
- Persistent Neurodegenerative Pathways: Similar to normal cells, pathways associated with neurodegenerative diseases are prominently enriched. This further strengthens the hypothesis that these pathways represent general cellular stress responses, protein quality control issues, or metabolic dysregulation that are exacerbated in the tumor microenvironment.
- Cell Cycle Regulation: Cell cycle pathway enrichment, while low on the list, is a fundamental aspect of cancer cell proliferation.
Clinical or Translational Implications
The GSA results provide valuable insights into the biological underpinnings of breast cancer and offer potential avenues for therapeutic exploration:
- Metabolic Vulnerabilities: The strong enrichment of Oxidative phosphorylation, mTOR signaling pathway, and various metabolic processes in primary tumor epithelial cells suggests that targeting these pathways could disrupt cancer cell energy supply and proliferation. Inhibitors of mTOR (e.g., everolimus) or agents affecting mitochondrial metabolism could be considered. PubMed search: mTOR signaling breast cancer
- Protein Homeostasis Stress: The activation of ER stress, autophagy, and proteasomal degradation pathways highlights that tumor cells operate under significant proteotoxic stress. Targeting these protein quality control mechanisms (e.g., proteasome inhibitors, autophagy inhibitors) could selectively induce cell death in cancer cells.
- Role of Cellular Adhesion: The unexpected enrichment of Tight junction and Adherens junction in tumor cells warrants further investigation. Understanding the specific context and function of these junctions in breast cancer could reveal new targets for inhibiting invasion or metastasis, as these structures are typically associated with stable epithelial phenotypes.
- Interpreting "Neurodegenerative Pathways": The consistent presence of pathways associated with neurodegenerative diseases across different epithelial cell comparisons, and particularly in tumor cells, suggests a shared cellular stress or metabolic dysfunction signature. Investigating the specific genes driving these enrichments could identify common mechanisms that contribute to cellular pathology in both neurodegeneration and cancer, potentially revealing novel targets related to mitochondrial function, oxidative stress, or protein aggregation. PubMed search: oxidative stress mitochondrial dysfunction cancer
- Ploidy as a Biomarker: The distinct set of enriched immune and viral response pathways in diploid epithelial cells suggests that genomic stability might correlate with different immune landscapes or responses, which could have implications for immunotherapy sensitivity.
21. Gene Set Enrichment Analysis Reveals Widespread Pathway Dysregulation in Breast Cancer Microenvironment
[Analysis Visualization Results]...
Analysis Overview
This analysis presents Gene Set Enrichment Analysis (GSEA) results for six key cell types (Endothelial cell, Epithelial cell, Fibroblast, ILC, Macrophage, and Smooth muscle cell) within the breast tissue context. The comparisons are primarily between primary tumor and normal conditions for each cell type, with an additional comparison for Epithelial cells based on ploidy status (Diploid vs. others, likely Aneuploid). The dot plot visualizes the Normalized Enrichment Score (NES) and statistical significance (-log(P)) for a curated set of 80 gene sets, providing insight into activated (red dots) or suppressed (blue dots) biological pathways.
Visual Summary
The dot plot effectively illustrates distinct patterns of pathway enrichment and depletion across different cell types and conditions.
- Color Scale: Red dots represent pathways with a positive NES, indicating enrichment in the test condition (e.g., primary tumor) compared to the reference (normal). Blue dots represent negative NES, indicating depletion. The intensity of the color reflects the magnitude of the NES.
- Dot Size: The size of each dot correlates with the statistical significance of the enrichment, with larger dots indicating more significant p-values (-log(P)).
- Overall Pattern: A prevalent pattern of strong red dots (enriched pathways) is observed across most cell types when comparing the primary tumor condition to normal. Conversely, the "normal_vs_others" comparisons for the same cell types largely show blue dots (depleted pathways) for the same sets of genes, confirming the tumor-driven nature of these enrichments.
- Epithelial Cell Ploidy Comparison: The "Epithelial cell: Diploid_vs_others" column shows a notable contrast, with many pathways enriched in primary tumor epithelial cells being depleted in diploid epithelial cells, suggesting that aneuploid cells drive these specific pathway activations.
Biological Interpretation
Widespread Activation of Proliferation, Metabolic, and Signaling Pathways in the Tumor Microenvironment
Across Epithelial cells, Fibroblasts, Macrophages, Endothelial cells, and Smooth muscle cells from primary tumors, a consistent and significant enrichment (large red dots) is observed for pathways central to cancer progression:
- Cellular Proliferation and Anabolism: Pathways such as DNA replication, Ribosome biogenesis in eukaryotes, RNA transport, and Spliceosome are highly enriched. This indicates a high rate of cell division, protein synthesis, and RNA processing across various cell types within the tumor, reflecting active growth of both cancer cells and their supporting stromal/immune components.
- Metabolic Reprogramming: Significant enrichments are seen in pathways like Glutathione metabolism, Biosynthesis of unsaturated fatty acids, Glycine, serine and threonine metabolism, Pentose phosphate pathway, Purine metabolism, and Pyrimidine metabolism. These findings underscore the profound metabolic rewiring within the tumor microenvironment, enabling rapid biomass accumulation and energy production to support aggressive proliferation and adaptation to stress. Autophagy and Mitophagy pathways are also frequently enriched, suggesting altered cellular recycling and energy dynamics.
- Key Signaling Cascades: MAPK signaling pathway, Hippo signaling pathway, TGF-beta signaling pathway, and Calcium signaling pathway are consistently enriched. These pathways are crucial regulators of cell growth, survival, differentiation, and cellular interactions, all of which are commonly dysregulated in cancer.
- Transcriptional Regulation: The enrichment of Basal transcription factors and Transcriptional misregulation in cancer pathways highlights extensive alterations in gene expression programs driving oncogenic processes.
Differential Pathway Activity in Aneuploid vs. Diploid Epithelial Cells
The comparison of Epithelial cell: Diploid_vs_others (likely Diploid vs. Aneuploid epithelial cells) provides critical insights into the molecular characteristics linked to ploidy status:
- Aneuploidy-Associated Oncogenic Activation: Most of the pro-tumorigenic pathways strongly enriched in primary tumor epithelial cells (e.g., DNA replication, Spliceosome, RNA transport, Ribosome biogenesis, Transcriptional misregulation in cancer, Hippo signaling, MAPK signaling, TGF-beta signaling, Autophagy, Glutathione metabolism) are significantly *depleted* in Diploid epithelial cells. This strongly suggests that the Aneuploid epithelial cell population is the primary driver of these aggressive, cancer-associated molecular programs.
- Diploid Cell Metabolism: Interestingly, Diploid epithelial cells show enrichment for certain metabolic pathways such as Glycolysis/gluconeogenesis, Pentose phosphate pathway, Purine metabolism, Pyrimidine metabolism, and N-Glycan biosynthesis. This may indicate a distinct metabolic state or a higher reliance on these pathways for basal functions in non-aneuploid (potentially less transformed) epithelial cells within the tumor context.
Cell-Type Specific Contributions to the Tumor Microenvironment
- Fibroblasts (CAFs): Strong enrichments in proliferation, metabolic, and signaling pathways similar to epithelial cells suggest that Tumor-Associated Fibroblasts (CAFs) are highly activated and play a crucial role in supporting tumor growth and remodeling the extracellular matrix.
- Macrophages (TAMs): Tumor-associated macrophages (TAMs) also exhibit robust activation of proliferation-related and metabolic pathways. Furthermore, enrichment in immune-related pathways like Fc epsilon RI signaling pathway and various infection pathways (e.g., *Pathogenic Escherichia coli infection*, *Staphylococcus aureus infection*) indicates a pro-inflammatory or altered immune response state, which is characteristic of TAMs that contribute to immunosuppression and tumor progression.
- Endothelial Cells: Enrichment of growth and metabolic pathways in tumor endothelial cells is consistent with active angiogenesis, a process vital for supplying nutrients to the growing tumor. Depletion of "Fluid shear stress and atherosclerosis" in tumor endothelial cells could reflect the abnormal and chaotic vascular architecture within tumors.
- ILCs and Smooth Muscle Cells: While ILCs show fewer strong enrichments compared to other cell types, some proliferation-related pathways are still active. Smooth muscle cells in the tumor also show activation of proliferation and signaling pathways, indicating their involvement in stromal remodeling.
Clinical or Translational Implications
The pervasive activation of proliferation, metabolic, and key signaling pathways across multiple cell types in the breast tumor microenvironment has significant clinical implications:
- Multi-target Therapeutic Strategies: The finding that common oncogenic pathways (e.g., MAPK, Hippo, TGF-beta) and metabolic vulnerabilities are shared across cancer cells, CAFs, TAMs, and endothelial cells suggests that therapies targeting these pathways could have broad anti-tumor effects by disrupting multiple components of the tumor ecosystem.
- Aneuploidy as a Prognostic Marker and Therapeutic Target: The distinct GSEA profiles linked to ploidy highlight aneuploidy as a key driver of aggressive tumor biology. Further research into the unique vulnerabilities of aneuploid epithelial cells could lead to highly targeted therapies that selectively eliminate the most malignant cell populations while sparing diploid cells.
- Immunomodulation: The altered pathway activity in tumor-associated macrophages (TAMs) points towards their role in shaping the immune landscape. Targeting specific immune-related pathways in TAMs could re-educate these cells to become anti-tumorigenic, enhancing immunotherapy efficacy.
- Metabolic Intervention: The consistent metabolic rewiring across the tumor microenvironment suggests that metabolic inhibitors, targeting pathways like glutathione synthesis or nucleotide metabolism, could be effective in starving tumor cells and their supporting stroma.
This comprehensive GSEA provides a detailed molecular fingerprint of the breast tumor microenvironment, emphasizing the interconnectedness of different cell types in driving disease progression and identifying potential common vulnerabilities for therapeutic exploitation.
22. Discussion
The comprehensive single-cell analysis reveals a striking and multifaceted transformation from normal breast tissue to primary breast cancer, encompassing cellular composition, genomic stability, intercellular communication, and functional pathway activity. UMAP visualizations consistently delineate distinct cellular landscapes for normal and primary tumor conditions, with aneuploid epithelial cells being a hallmark feature predominantly confined to the tumor compartment. This genomic instability in epithelial cells, designated as the tumor origin, is further substantiated by extensive recurrent copy number variations (CNVs) in primary tumor samples, notably amplifications on chromosomes 1q, 7p/q, and 8q, implicating genes like NFASC and EIF3E in tumor progression.
The tumor microenvironment (TME) undergoes profound remodeling, evidenced by significant shifts in cell type proportions. While normal tissue is dominated by epithelial cells, primary tumors show a reduced epithelial fraction alongside a notable increase in stromal cells, particularly cancer-associated fibroblasts (CAFs), and diverse immune populations, including macrophages (tumor-associated macrophages, TAMs) and various T cell subsets. Functional analysis of these infiltrating immune cells indicates an altered immune landscape in tumors, with increased proportions of Th2 and T follicular helper (Tfh) cells and a decrease in Lymphoid Tissue inducer (LTI) cells, collectively suggesting a shift towards immunosuppression and potential disruption of organized lymphoid structures, while also reflecting active B cell responses. Macrophages within the TME also exhibit a distinct surfaceome profile, characterized by upregulation of pro-tumorigenic markers such as EREG, CXCR4, and MET, distinguishing them from normal tissue macrophages.
Cell-cell interaction (CCI) analyses unveil a dramatically denser and more complex communication network in primary tumors compared to normal tissue. Aneuploid epithelial cells actively engage in extensive crosstalk with CAFs, endothelial cells, and TAMs, underscoring their role in shaping the TME. A central finding is the widespread upregulation of extracellular matrix (ECM)-integrin interactions, involving various collagens and fibronectin, which signifies extensive ECM remodeling crucial for tumor cell adhesion, migration, and invasion. Angiogenic pathways (e.g., VEGF-VEGFR, PGF-FLT1) are highly activated in tumor endothelial cells, supporting neovascularization. Chemokine signaling, particularly the CXCL12-CXCR4 and CCL2-CCR2 axes, is enhanced, facilitating the recruitment of immune and stromal cells. Furthermore, TGF-beta signaling is pervasively activated in the primary tumor, notably through integrin αvβ6-mediated activation of latent TGF-beta, contributing to fibrosis, immune suppression, and epithelial-stromal crosstalk. In contrast, normal tissue CCIs are more sparse and reflect homeostatic processes and baseline immune surveillance, such as ProstaglandinE2 and SIRPA-CD47 signaling.
Functional pathway analyses (GSEA and GSA) corroborate these findings, revealing widespread pathway dysregulation across tumor-associated cell types. Primary tumor epithelial cells, CAFs, and TAMs consistently exhibit significant enrichment in pathways related to cellular proliferation (DNA replication, ribosome biogenesis), metabolic reprogramming (oxidative phosphorylation, purine/pyrimidine metabolism, glutathione metabolism), and key signaling cascades (MAPK, Hippo, mTOR, TGF-beta). This pervasive metabolic and signaling rewiring supports aggressive tumor growth and adaptation to the challenging TME. Notably, these pro-oncogenic programs are predominantly driven by the aneuploid epithelial cell population, as evidenced by their depletion in diploid epithelial cells. The significant upregulation of YWHAZ, a cell cycle regulator, in tumor epithelial cells further underscores the heightened proliferative drive. An intriguing and recurrent finding from Gene Ontology analysis is the enrichment of pathways associated with neurodegenerative diseases in both normal and tumor epithelial cells. While unexpected, this may point to shared fundamental cellular stress responses, mitochondrial dysfunction, or protein aggregation mechanisms that are potentially exacerbated in cancer. Collectively, these results highlight the intricate interplay between malignant cells and their microenvironment, driven by genomic instability, extensive cellular communication, and metabolic adaptation, which underpins breast cancer progression.
Hypotheses:
- Aneuploidy in breast epithelial cells is a primary driver of the observed tumor-specific transcriptional programs, cell-cell interaction patterns, and metabolic dysregulation within the tumor microenvironment.
- The extensive extracellular matrix remodeling and increased integrin-mediated interactions in primary breast tumors create a pro-tumorigenic niche that promotes cancer cell invasion, metastasis, and therapeutic resistance.
- The altered T cell subset composition (increased Th2 and Tfh, decreased LTI) and phenotypic shift of tumor-associated macrophages contribute to an immunosuppressive microenvironment, facilitating immune evasion and tumor progression.
- Hyperactivated TGF-beta signaling, particularly through integrin αvβ6 activation, plays a central role in promoting fibrosis, immune suppression, and epithelial-stromal crosstalk in breast cancer.
- The upregulation of YWHAZ in primary tumor epithelial cells contributes to uncontrolled cell cycle progression and survival, serving as a critical hub in the malignant transformation.
Potential therapeutic targets:
- TGF-beta Pathway (Ligands/Receptors/Activation via Integrin αvβ6): Consistently identified as highly active and pervasive in the primary tumor microenvironment, especially involving aneuploid epithelial cells and fibroblasts. Integrin αvβ6-mediated activation of latent TGF-beta is also prominent, indicating robust local signaling that promotes tumor growth, immune evasion, and fibrosis. Evidence: CCI analyses (Sections 11, 12, 13) show strong TGFB1-TGFbeta_receptor1/2 and TGFB1_integrin_avB6_complex interactions in primary tumor. GSA and GSEA (Sections 20, 21) also show enrichment of TGF-beta signaling pathway. Validation: Test TGF-beta inhibitors or αvβ6-integrin blocking antibodies in *in vitro* co-culture models of tumor cells and CAFs, or *in vivo* PDX models. Assess impact on tumor growth, invasion, fibrosis, and immune infiltration.
- Integrin-mediated ECM interactions (e.g., Collagen-Integrin, Fibronectin-Integrin complexes): Extensive upregulation of various collagen-integrin and fibronectin-integrin interactions in primary tumors, often involving aneuploid epithelial cells and fibroblasts. These interactions are critical for ECM remodeling, cell adhesion, migration, and invasion, central to metastasis and tumor progression. Evidence: CCI analyses (Sections 11, 12, 14) show robust upregulation of COL6A1/A2/A3/18A1-integrin_a1b1/a2b1/a3b1/avb5/a5b1_complex and FN1-integrin_a5b1_complex in primary tumors. Validation: Develop or repurpose specific integrin inhibitors (e.g., targeting α1β1, α2β1, α5β1, αVβ5) and test their efficacy in blocking tumor cell invasion, migration, and metastasis in *in vitro* assays and *in vivo* models. Assess effects on tumor stiffness and ECM architecture.
- NECTIN4 (on Epithelial Cells): NECTIN4 is a surface protein highly and specifically upregulated on primary tumor epithelial cells, serving as a distinct tumor-associated antigen. It is implicated in increased invasiveness and its surface accessibility makes it an ideal therapeutic target. Evidence: Section 15 identifies NECTIN4 as a highly expressed and prevalent condition-specific surfaceome marker in primary tumor epithelial cells (dark red dots, large sizes). Validation: Evaluate NECTIN4-targeting antibody-drug conjugates (ADCs) or monoclonal antibodies in preclinical breast cancer models. Assess their ability to inhibit tumor growth and metastasis. Confirm NECTIN4 expression by immunohistochemistry in patient cohorts.
- CXCR4 (on Macrophages and Fibroblasts): CXCR4 is a chemokine receptor upregulated in tumor-associated macrophages and involved in significant cell-cell interactions (e.g., CXCL12-CXCR4) with fibroblasts and T cells in primary tumors. It plays roles in tumor growth, metastasis, and immune cell trafficking, contributing to an immunosuppressive TME. Evidence: CCI analyses (Sections 11, 12) show robust CXCL12-CXCR4 interactions in primary tumor. Section 16 identifies CXCR4 as a condition-specific surfaceome marker for macrophages in tumors. Validation: Use CXCR4 antagonists to evaluate their effect on TAM recruitment to the tumor, macrophage polarization, tumor growth, and metastasis in *in vivo* models. Combine with immune checkpoint inhibitors to assess synergistic effects.
- YWHAZ (on Epithelial Cells): YWHAZ, a member of the 14-3-3 protein family, is a key cell cycle regulator significantly upregulated in primary tumor epithelial cells (tumor origin cell type), indicative of its role in driving uncontrolled proliferation and survival, hallmarks of cancer. Evidence: Section 19 presents boxplots showing significantly elevated YWHAZ expression in primary tumor epithelial cells compared to normal (p ≤ 0.001). Validation: Perform *in vitro* functional studies using siRNA/CRISPR to deplete YWHAZ in breast cancer cell lines and assess effects on cell proliferation, apoptosis, and cell cycle progression. Validate *in vivo* in PDX models.
Follow-up validation ideas:
- Validate recurrent CNV regions (e.g., 1q, 8q amplifications, specific genes like NFASC, EIF3E) in larger cohorts of breast cancer patient samples using FISH or array CGH, correlating with patient outcomes and specific tumor subtypes.
- Apply spatial transcriptomics or multiplex immunofluorescence/proteomics to breast tumor tissues to validate the spatial localization of specific cell types (e.g., FAP+ CAFs, CD163+ TAMs, NECTIN4+ epithelial cells) and key ligand-receptor interactions (e.g., SPP1-integrin, CXCL12-CXCR4, TGFB1-integrin_avB6_complex) identified by CCI analysis.
- Quantify and functionally characterize T cell subsets (Th2, LTI, Tfh) and macrophage polarizations (M1/M2 markers like CD163, EREG, CXCR4, MET) in fresh tumor biopsies and matched normal tissue using flow cytometry or high-plex immunostaining, correlating with clinical outcomes.
- Conduct perturbation assays (in vitro/in vivo) such as co-culture experiments with patient-derived tumor epithelial cells, CAFs, and TAMs to functionally validate key CCIs (e.g., blocking TGF-beta signaling, integrin antagonists, CXCR4 inhibitors) and their impact on tumor cell proliferation, migration, and immune cell function. Use in vivo patient-derived xenograft (PDX) or syngeneic mouse models with gene editing (CRISPR/shRNA) to target upregulated genes (e.g., YWHAZ, FAP, NECTIN4, EGFR, ERBB3) in tumor or stromal cells, followed by assessing tumor growth, metastasis, and immune infiltration.
- Perform metabolic flux analysis on isolated tumor epithelial cells, CAFs, and TAMs to validate the predicted metabolic reprogramming (e.g., oxidative phosphorylation, glutathione metabolism) and identify specific metabolic vulnerabilities that can be therapeutically targeted.
Limitations:
This report is based on single-cell RNA sequencing data, providing transcriptomic insights which infer cellular function and interactions; direct functional consequences require experimental validation. CNV estimates derived from RNA-seq are inferential and would benefit from orthogonal genomic validation methods. Cell-cell interaction predictions from CellPhoneDB suggest potential communication but require experimental confirmation of physical contact and functional impact. The inherent heterogeneity among patient samples and the specific dataset size may limit the generalizability of some findings. While minor, 'unassigned' cell populations could harbor uncharacterized cell states. Lastly, observational data cannot establish causality, and further mechanistic studies are necessary to elucidate the precise roles of identified targets and pathways in breast cancer progression.
23. Query List
- Show UMAPs including condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in 2 columns and save.
- Show major cell type scores on UMAP and save.
- Show the overall Celltype_subset marker expression dot plot and save it. Keep target_cell as None and keep the other arguments at their default values.
- Select tumor origin cells and unassigned cells, group them by sample, show a CNV heatmap, and also show a summary of significantly amplified copy number regions, and save.
- Show CNV patterns on UMAP, including major cell type, minor cell type, ploidy results, condition, and sample in 2 columns, and save.
- Show a population bar plot of minor cell types and save.
- Show a subset population bar plot for T cells and save.
- If there are statistically significant differences between conditions in T cell subset populations, show boxplots and save. Set ncols appropriately based on the total number of panels.
- Show a subset population bar plot for Macrophages and save.
- Select tumor origin cells and unassigned cells, show their ploidy population as a bar plot, and save.
- Show cell-cell interaction patterns including Epithelial cell, Fibroblast, Macrophage, and T cell by condition, and save. For cell-cell interactions, select up to 80 interactions per condition.
- Show cell-cell interactions by condition and save the result. Select at most 80 cell-cell interactions for each condition.
- Select only genes related to immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save.
- Find statistically significant differences in cell-cell interactions between conditions for T cell, Myeloid cell, Stromal cell, Endothelial cell, and Mast cell, show them as a dot plot, and save. Set max_n_items_per_group = 25.
- Show the condition-specific markers for tumor-origin cells (Epithelial cell) as a dot plot and save the result. Use only surfaceome markers, up to 50 markers per condition.
- Extract condition-specific markers for Macrophage, show them as a dot plot, and save. Only surfaceome markers, up to 50 per condition.
- Extract condition-specific markers for Fibroblast, show them as a dot plot, and save. Only surfaceome markers, up to 50 per condition.
- Extract condition-specific markers for T cell CD4+, show them as a dot plot, and save. Only surfaceome markers, up to 50 per condition.
- For genes related to the Cell cycle pathway, for Epithelial cell, Fibroblast, and Macrophage, show boxplots of statistically significant expression differences between conditions, and save. Set max_n_items_to_plot = 24, and ncols appropriately so that the width:height ratio is about 2:3 based on the total number of panels.
- Show Gene Ontology (GSA) analysis results for epithelial cells as bar plots and save the result.
- Show a dot plot of Gene set enrichment analysis results for Endothelial cell, Epithelial cell, Fibroblast, ILC, Macrophage, and Smooth muscle cell, and save. Use RdBu_r as the color map, and set n_pws_to_show = 80.



















